https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=0
Page 0 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "drug_interactions": [
        "Drug Interactions Since Cilostazol Tablets, USP is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when Cilostazol Tablets, USP is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol Tablets, USP does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to CYP3A4 inhibition."
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2274 patients exposed to either 50 or 100 mg b.i.d. cilostazol tablets (n=1301) or placebo (n=973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >= 3% of patients treated with cilostazol 50 or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with cilostazol 50 mg b.i.d., 100 mg b.i.d. or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >= 2% of patients treated with cilostazol 50 or 100 mg b.i.d., are shown in the table below. Other events seen with an incidence of >= 2%, but occurring in the placebo group at least as frequently as in the 100 mg b.i.d. group were: asthenia, hypertension, vomiting, leg cramps, hyperesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. Most Commonly Reported AEs (Incidence >=2%) in Patients on Cilostazol 50 mg b.i.d. or 100 mg b.i.d. and Occurring at a Rate in the 100 mg b.i.d. Group Higher Than in Patients on Placebo Adverse Events (AEs) by Body System Cilostazol 50 mg b.i.d. (N=303) % Cilostazol 100 mg b.i.d. (N=998) % Placebo (N=973) % BODY AS A WHOLE Abdominal pain 4 5 3 Back pain 6 7 6 Headache 27 34 14 Infection 14 10 8 CARDIOVASCULAR Palpitation 5 10 1 Tachycardia 4 4 1 DIGESTIVE Abnormal stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 METABOLIC & NUTRITIONAL Peripheral edema 9 7 4 MUSCULO-SKELETAL Myalgia 2 3 2 NERVOUS Dizziness 9 10 6 Vertigo 3 1 1 RESPIRATORY Cough increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (< 2%) that were experienced by patients exposed to cilostazol 50 mg b.i.d. or 100 mg b.i.d. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg b.i.d. group greater than in the placebo group, regardless of suspected drug relationship, are listed below. Body As a Whole: Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal hemorrhage. Cardiovascular: Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, hemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Digestive: Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal hemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum hemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal hemorrhage, stomach ulcer, tongue edema. Endocrine: Diabetes mellitus. Hemic and Lymphatic: Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Metabolic and Nutritional:: Increased creatinine, gout, hyperlipemia, hyperuricemia. Musculoskeletal: Arthralgia, bone pain, bursitis. Nervous: Anxiety, insomnia, neuralgia. Respiratory: Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Skin and Appendages: Dry skin, furunculosis, skin hypertrophy, urticaria. Special Senses: Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye hemorrhage, retinal hemorrhage, tinnitus. Urogenital: Albuminuria, cystitis, urinary frequency, vaginal hemorrhage, vaginitis Post Marketing Experience The following adverse events have been reported spontaneously from worldwide post-marketing experience since launch of cilostazol in the US. Blood and lymphatic system disorders: agranulocytosis, aplastic anemia, granulocytopenia, thrombocytopenia, leukopenia, bleeding tendency Cardiac disorders: Torsades de pointes, QTc prolongation (Torsades de pointes and QTc prolongation occurred in patients with cardiac disorders, e.g. complete atrioventricular block, cardiac failure and bradyarrythmia, when treated with cilostazol. Cilostazol was used "off label" due to its positive chronotropic action.) Gastrointestinal disorders: gastrointestinal hemorrhage General disorders and administration site conditions: pain, chest pain, hot flushes Hepatobiliary disorders: hepatic dysfunction/abnormal liver function tests, jaundice Injury, poisoning and procedural complications: extradural hematoma and subdural hematoma Investigations : blood glucose increased, blood uric acid increased, platelet count decreased, white blood cell count decreased, increase in BUN (blood urea increased), blood pressure increase Nervous system disorders: intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident Respiratory, thoracic and mediastinal disorders: pulmonary hemorrhage, interstitial pneumonia Skin and subcutaneous tissue disorders: hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa) Vascular disorders: subacute thrombosis (These cases of subacute thrombosis occurred in patients treated with aspirin and "off label" use of cilostazol for prevention of thrombotic complication after coronary stenting.)"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=1
Page 1 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "CILOSTAZOL"
 
      "drug_interactions": [
        "Drug Interactions : Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to CYP3A4 inhibition."
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2274 patients exposed to either 50 or 100 mg b.i.d. cilostazol tablets (n=1301) or placebo (n=973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >= 3% of patients treated with cilostazol 50 or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with cilostazol 50 mg b.i.d., 100 mg b.i.d. or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >= 2% of patients treated with cilostazol 50 or 100 mg b.i.d., are shown in the table below. Other events seen with an incidence of >= 2%, but occurring in the placebo group at least as frequently as in the 100 mg b.i.d. group were: asthenia, hypertension, vomiting, leg cramps, hyperesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. Most Commonly Reported AEs (Incidence >=2%) in Patients on Cilostazol 50 mg b.i.d. or 100 mg b.i.d. and Occurring at a Rate in the 100 mg b.i.d. Group Higher Than in Patients on Placebo Adverse Events (AEs) by Body System Cilostazol 50 mg b.i.d. (N=303) % Cilostazol 100 mg b.i.d. (N=998) % Placebo (N=973) % BODY AS A WHOLE Abdominal pain 4 5 3 Back pain 6 7 6 Headache 27 34 14 Infection 14 10 8 CARDIOVASCULAR Palpitation 5 10 1 Tachycardia 4 4 1 DIGESTIVE Abnormal stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 METABOLIC & NUTRITIONAL Peripheral edema 9 7 4 MUSCULO-SKELETAL Myalgia 2 3 2 NERVOUS Dizziness 9 10 6 Vertigo 3 1 1 RESPIRATORY Cough increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (< 2%) that were experienced by patients exposed to cilostazol 50 mg b.i.d. or 100 mg b.i.d. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg b.i.d. group greater than in the placebo group, regardless of suspected drug relationship, are listed below. Body As a Whole: Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal hemorrhage. Cardiovascular: Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, hemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Digestive: Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal hemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum hemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal hemorrhage, stomach ulcer, tongue edema. Endocrine: Diabetes mellitus. Hemic and Lymphatic: Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Metabolic and Nutritional:: Increased creatinine, gout, hyperlipemia, hyperuricemia. Musculoskeletal: Arthralgia, bone pain, bursitis. Nervous: Anxiety, insomnia, neuralgia. Respiratory: Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Skin and Appendages: Dry skin, furunculosis, skin hypertrophy, urticaria. Special Senses: Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye hemorrhage, retinal hemorrhage, tinnitus. Urogenital: Albuminuria, cystitis, urinary frequency, vaginal hemorrhage, vaginitis."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=2
Page 2 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "drug_interactions": [
        "Drug Interactions Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (seeCLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to CYP3A4 inhibition."
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2274 patients exposed to either 50 or 100 mg b.i.d. cilostazol (n=1301) or placebo (n=973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >= 3% of patients treated with cilostazol 50 or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with cilostazol 50 mg b.i.d., 100 mg b.i.d, or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >= 2% of patients treated with cilostazol 50 or 100 mg b.i.d., are shown in the table (below). Other events seen with an incidence of >= 2%, but occurring in the placebo group at least as frequently as in the 100 mg b.i.d. group were: asthenia, hypertension, vomiting, leg cramps, hyperesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. Most Commonly Reported AEs (Incidence >=2%) in Patients on Cilostazol 50 mg b.i.d. or 100 mg b.i.d. and Occurring at a Rate in the 100 mg b.i.d. Group Higher Than in Patients on Placebo Adverse Events (AEs) by Body System Cilostazol 50 mg b.i.d. (N=303) % Cilostazol 100 mg b.i.d. (N=998) % Placebo (N=973) % BODY AS A WHOLE Abdominal pain 4 5 3 Back pain 6 7 6 Headache 27 34 14 Infection 14 10 8 CARDIOVASCULAR Palpitation 5 10 1 Tachycardia 4 4 1 DIGESTIVE Abnormal stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 METABOLIC & NUTRITIONAL Peripheral edema 9 7 4 MUSCULO-SKELETAL Myalgia 2 3 2 NERVOUS Dizziness 9 10 6 Vertigo 3 1 1 RESPIRATORY Cough increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (<2%) that were experienced by patients exposed to cilostazol 50 mg b.i.d. or 100 mg b.i.d. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg b.i.d. group greater than in the placebo group, regardless of suspected drug relationship, are listed below. Body As a Whole Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal hemorrhage. Cardiovascular Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, hemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Digestive Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal hemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum hemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal hemorrhage, stomach ulcer, tongue edema. Endocrine Diabetes mellitus. Hemic and Lymphatic Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Metabolic and Nutritional Increased creatinine, gout, hyperlipemia, hyperuricemia. Musculoskeletal Arthralgia, bone pain, bursitis. Nervous Anxiety, insomnia, neuralgia. Respiratory Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Skin and Appendages Dry skin, furunculosis, skin hypertrophy, urticaria. Special Senses Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye hemorrhage, retinal hemorrhage, tinnitus. Urogenital Albuminuria, cystitis, urinary frequency, vaginal hemorrhage, vaginitis. Post-Marketing Experience The following events have been reported spontaneously from worldwide post-marketing experience since the launch of cilostazol in the US. Blood and lymphatic system disorders - agranulocytosis, aplastic anemia, granulocytopenia, thrombocytopenia, leukopenia, bleeding tendency Cardiac disorders - Torsades de pointes, QTc prolongation (Torsades de pointes and QTc prolongation occurred in patients with cardiac disorders, e.g. complete atrioventricular block, cardiac failure and bradyarrythmia, when treated with cilostazol. Cilostazol was used "off label" due to its positive chronotropic action.) Gastrointestinal disorders - gastrointestinal haemorrhage General disorders and administration site conditions - pain, chest pain, hot flushes Hepatobiliary disorders - hepatic dysfunction/abnormal liver function tests, jaundice Injury, poisoning and procedural complications - extradural haematoma and subdural haematoma Investigations - blood glucose increased, blood uric acid increased, platelet count decreased, white blood cell count decreased, increase in BUN (blood urea increased), blood pressure increase Nervous system disorders - intracranial haemorrhage, cerebral haemorrhage, cerebrovascular accident Respiratory, thoracic and mediastinal disorders - pulmonary haemorrhage, interstitial pneumonia Skin and subcutaneous tissue disorders - haemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa) Vascular disorders - subacute thrombosis (These cases of subacute thrombosis occurred in patients treated with aspirin and "off label" use of cilostazol for prevention of thrombotic complication after coronary stenting.)"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=3
Page 3 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "drug_interactions": [
        "7 DRUG INTERACTIONS - Strong and moderate CYP3A4 and CYP2C19 inhibitors: Increase exposure to cilostazol. Reduce cilostazol dose (2.2, 7.1) 7.1 Inhibitors of CYP3A4 or CYP2C19 Inhibitors of CYP3A4 Coadministration of strong (e.g., ketoconazole) and moderate (e.g., erythromycin, diltiazem and grapefruit juice) CYP3A4 inhibitors can increase exposure to cilostazol. Reduce cilostazol dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP3A4 [see DOSAGE AND ADMINISTRATION ( 2.2) and CLINICAL PHARMACOLOGY ( 12.3)]. Inhibitors of CYP2C19 Coadministration with CYP2C19 inhibitors (e.g., omeprazole) increases systemic exposure of cilostazol active metabolites. Reduce cilostazol dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP2C19 [see DOSAGE AND ADMINISTRATION ( 2.2) and CLINICAL PHARMACOLOGY ( 12.3)]."
      "adverse_reactions": [
        "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: - Patients with Heart Failure [see BOXED WARNING] - Tachycardia [see WARNINGS AND PRECAUTIONS ( 5.1)] - Hematologic Adverse Reactions [see WARNINGS AND PRECAUTIONS ( 5.2)] - Hemostatic Disorders or Active Pathologic Bleeding [see WARNINGS AND PRECAUTIONS ( 5.3)] Most common adverse reactions greater than or equal to 2% and at least twice that for placebo in patients on 100 mg twice daily are headache, diarrhea, abnormal stools, and palpitation (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions were assessed in eight placebo-controlled clinical trials involving patients exposed to either 50 mg or 100 mg twice daily cilostazol (n=1,301) or placebo (n=973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The most frequent adverse reaction resulting in discontinuation of therapy in more than 3% of patients treated with cilostazol was headache [50 mg twice daily (1.3%), 100 mg twice daily (3.5%) and placebo (0.3%)]. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most common adverse reactions, occurring in at least 2% of patients treated with cilostazol 50 mg or 100 mg twice daily, are shown in Table 1. Table 1 Most Common Adverse Reactions in Patients on Cilostazol 50 mg or 100 mg Twice Daily (Incidence at least 2% and Occurring More Frequently (greater than or equal to 2%) in the 100 mg Twice Daily Group than on Placebo) Adverse Reactions Placebo (N=973) Cilostazol 50 mg twice daily (N=303) Cilostazol 100 mg twice daily (N=998) Headache 14% 27% 34% Diarrhea 7% 12% 19% Abnormal stools 4% 12% 15% Palpitation 1% 5% 10% Dizziness 6% 9% 10% Pharyngitis 7% 7% 10% Infection 8% 14% 10% Peripheral edema 4% 9% 7% Rhinitis 5% 12% 7% Dyspepsia 4% 6% 6% Abdominal pain 3% 4% 5% Tachycardia 1% 4% 4% Less frequent clinical significant adverse reactions (less than 2%) that were experienced by patients treated with cilostazol 50 mg twice daily or 100 mg twice daily in the eight controlled clinical trials and that occurred at a frequency in the 100 mg twice daily group greater than in the placebo group are listed below. Body as a whole Fever, generalized edema, malaise Cardiovascular Atrial fibrillation, heart failure, myocardial infarction, nodal arrhythmia, supraventricular tachycardia, ventricular extrasystoles, ventricular tachycardia Digestive Anorexia, melena Hematologic and Lymphatic Anemia Metabolic and Nutritional Increased creatinine, hyperuricemia Nervous Insomnia Respiratory Epistaxis Skin and Appendages Urticaria Special Senses Conjunctivitis, retinal hemorrhage, tinnitus Urogenital Urinary frequency 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of cilostazol. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders Aplastic anemia, granulocytopenia, pancytopenia, bleeding tendency Cardiac disorders Torsade de pointes and QTc prolongation in patients with cardiac disorders (e.g., complete atrioventricular block, heart failure; and bradyarrythmia), angina pectoris. Gastrointestinal disorders Gastrointestinal hemorrhage, vomiting, flatulence, nausea General disorders and administration site conditions Pain, chest pain, hot flushes Hepatobiliary disorders Hepatic dysfunction/abnormal liver function tests, jaundice Immune system disorders Anaphylaxis, angioedema, and hypersensitivity Investigations Blood glucose increased, blood uric acid increased, increase in BUN (blood urea increased), blood pressure increase Nervous system disorders Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident, extradural hematoma and subdural hematoma Renal and urinary disorders Hematuria Respiratory, thoracic and mediastinal disorders Pulmonary hemorrhage, interstitial pneumonia Skin and subcutaneous tissue disorders Hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa), rash Vascular disorders Subacute stent thrombosis, hypertension."
      "warnings_and_cautions": [
        "5 WARNINGS AND PRECAUTIONS -Risks of tachycardia, palpitation, tachyarrhythmia or hypotension. Risks of exacerbations of angina pectoris or myocardial infarction in patients with a history of ischemic heart disease (5.1) -Risks of thrombocytopenia or leukopenia progressing to agranulocytosis--monitor platelets and white blood cell counts (5.2) -Avoid use in patients with hemostatic disorders or active pathologic bleeding (5.3) 5.1 Tachycardia Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension. The increase in heart rate associated with cilostazol is approximately 5 bpm to 7 bpm. Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction. 5.2 Hematologic Adverse Reactions Cases of thrombocytopenia or leukopenia progressing to agranulocytosis when cilostazol was not immediately discontinued have been reported. Agranulocytosis is reversible on discontinuation of cilostazol. Monitor platelets and white blood cell counts periodically. 5.3 Hemostatic Disorders or Active Pathologic Bleeding Cilostazol inhibits platelet aggregation in a reversible manner. Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding. Avoid use of cilostazol in these patients."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=4
Page 4 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "PLETAL"
 
      "drug_interactions": [
        "7 DRUG INTERACTIONS - Strong and moderate CYP3A4 and CYP2C19 inhibitors: Increase exposure to PLETAL. Reduce PLETAL dose (2.2, 7.1) 7.1 Inhibitors of CYP3A4 or CYP2C19 Inhibitors of CYP3A4 Coadministration of strong (e.g., ketoconazole) and moderate (e.g., erythromycin, diltiazem and grapefruit juice) CYP3A4 inhibitors can increase exposure to PLETAL. Reduce PLETAL dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP3A4 [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)]. Inhibitors of CYP2C19 Coadministration with CYP2C19 inhibitors (e.g., omeprazole) increases systemic exposure of PLETAL active metabolites. Reduce PLETAL dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP2C19 [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)]."
      "adverse_reactions": [
        "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail inother sections of the labeling: oPatients with Heart Failure [see Boxed Warning] oTachycardia [see Warnings and Precautions (5.1)] oHematologic Adverse Reactions [see Warnings and Precautions (5.2)] oHemostatic Disorders or Active Pathologic Bleeding [see Warnings and Precautions (5.3)] Most common adverse reactions greater than or equal to 2% and at least twice that for placebo in patients on 100 mg twice daily are headache, diarrhea, abnormal stools, and palpitation (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-877-438-9927 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions were assessed in eight placebo-controlled clinical trials involving patients exposed to either 50 or 100 mg twice daily PLETAL (n=1301) or placebo (n=973), with a median treatment duration of 127 days for patients on PLETAL and 134 days for patients on placebo. The most frequent adverse reaction resulting in discontinuation of therapy in more than 3% of patients treated with PLETAL was headache [50 mg twice daily (1.3%), 100 mg twice daily (3.5%) and placebo (0.3%)]. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for PLETAL (all doses) versus 0.1% for placebo. The most common adverse reactions, occurring in at least 2% of patients treated with PLETAL 50 or 100 mg twice daily, are shown in Table 1. Table 1: Most Common Adverse Reactions in Patients on PLETAL (PLT) 50 or 100 mg Twice Daily (Incidence at least 2% and Occurring More Frequently (>= 2%) in the 100 mg Twice Daily Group than on Placebo) Adverse Reactions Placebo (N=973) PLT 50 mg twice daily (N=303) PLT 100 mg twice daily (N=998) Headache 14% 27% 34% Diarrhea 7% 12% 19% Abnormal stools 4% 12% 15% Palpitation 1% 5% 10% Dizziness 6% 9% 10% Pharyngitis 7% 7% 10% Infection 8% 14% 10% Peripheral edema 4% 9% 7% Rhinitis 5% 12% 7% Dyspepsia 4% 6% 6% Abdominal pain 3% 4% 5% Tachycardia 1% 4% 4% Less frequent clinical significant adverse reactions (less than 2%) that were experienced by patients treated with PLETAL 50 mg twice daily or 100 mg twice daily in the eight controlled clinical trials and that occurred at a frequency in the 100 mg twice daily group greater than in the placebo group are listed below. Body as a whole: fever, generalized edema, malaise Cardiovascular: atrial fibrillation, heart failure, myocardial infarction, nodal arrhythmia, supraventricular tachycardia, ventricular extrasystoles, ventricular tachycardia Digestive: anorexia, melena Hematologic and Lymphatic: anemia Metabolic and Nutritional: increased creatinine, hyperuricemia Nervous: insomnia Respiratory: epistaxis Skin and Appendages: urticaria Special Senses: conjunctivitis, retinal hemorrhage, tinnitus Urogenital: urinary frequency 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of PLETAL. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: Aplastic anemia, granulocytopenia, pancytopenia, bleeding tendency Cardiac disorders: Torsade de pointes and QTc prolongation in patients with cardiac disorders (e.g. complete atrioventricular block, heart failure; and bradyarrythmia), angina pectoris. Gastrointestinal disorders: Gastrointestinal hemorrhage, vomiting, flatulence, nausea General disorders and administration site conditions: Pain, chest pain, hot flushes Hepatobiliary disorders: Hepatic dysfunction/abnormal liver function tests, jaundice Immune system disorders: Anaphylaxis, angioedema, and hypersensitivity Investigations: Blood glucose increased, blood uric acid increased, increase in BUN (blood urea increased), blood pressure increase Nervous system disorders: Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident, extradural hematoma and subdural hematoma Renal and urinary disorders: Hematuria Respiratory, thoracic and mediastinal disorders: Pulmonary hemorrhage, interstitial pneumonia Skin and subcutaneous tissue disorders: Hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa), rash Vascular disorders: Subacute stent thrombosis, hypertension."
      "warnings_and_cautions": [
        "5 WARNINGS AND PRECAUTIONS -Risks of tachycardia, palpitation, tachyarrhythmia or hypotension. Risks of exacerbations of angina pectoris or myocardial infarction in patients with a history of ischemic heart disease (5.1) -Risks of thrombocytopenia or leukopenia progressing to agranulocytosis-monitor platelets and white blood cell counts (5.2) -Avoid use in patients with hemostatic disorders or active pathologic bleeding (5.3) 5.1 Tachycardia Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension. The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm. Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction. 5.2 Hematologic Adverse Reactions Cases of thrombocytopenia or leukopenia progressing to agranulocytosis when PLETAL was not immediately discontinued have been reported. Agranulocytosis is reversible on discontinuation of PLETAL. Monitor platelets and white blood cell counts periodically. 5.3 Hemostatic Disorders or Active Pathologic Bleeding PLETAL inhibits platelet aggregation in a reversible manner. PLETAL has not been studied in patients with hemostatic disorders or active pathologic bleeding. Avoid use of PLETAL in these patients."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=5
Page 5 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "drug_interactions": [
        "7 DRUG INTERACTIONS - Strong and moderate CYP3A4 and CYP2C19 inhibitors: Increase exposure to cilostazol. Reduce cilostazol dose (2.2, 7.1) 7.1 Inhibitors of CYP3A4 or CYP2C19 Inhibitors of CYP3A4 Coadministration of strong (e.g., ketoconazole) and moderate (e.g., erythromycin, diltiazem and grapefruit juice) CYP3A4 inhibitors can increase exposure to cilostazol. Reduce cilostazol dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP3A4 [see DOSAGE AND ADMINISTRATION ( 2.2) and CLINICAL PHARMACOLOGY ( 12.3)]. Inhibitors of CYP2C19 Coadministration with CYP2C19 inhibitors (e.g., omeprazole) increases systemic exposure of cilostazol active metabolites. Reduce cilostazol dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP2C19 [see DOSAGE AND ADMINISTRATION ( 2.2) and CLINICAL PHARMACOLOGY ( 12.3)]."
      "adverse_reactions": [
        "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: - Patients with Heart Failure [see BOXED WARNING] - Tachycardia [see WARNINGS AND PRECAUTIONS ( 5.1)] - Hematologic Adverse Reactions [see WARNINGS AND PRECAUTIONS ( 5.2)] - Hemostatic Disorders or Active Pathologic Bleeding [see WARNINGS AND PRECAUTIONS ( 5.3)] Most common adverse reactions greater than or equal to 2% and at least twice that for placebo in patients on 100 mg twice daily are headache, diarrhea, abnormal stools, and palpitation (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions were assessed in eight placebo-controlled clinical trials involving patients exposed to either 50 mg or 100 mg twice daily cilostazol (n=1,301) or placebo (n=973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The most frequent adverse reaction resulting in discontinuation of therapy in more than 3% of patients treated with cilostazol was headache [50 mg twice daily (1.3%), 100 mg twice daily (3.5%) and placebo (0.3%)]. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most common adverse reactions, occurring in at least 2% of patients treated with cilostazol 50 mg or 100 mg twice daily, are shown in Table 1. Table 1 Most Common Adverse Reactions in Patients on Cilostazol 50 mg or 100 mg Twice Daily (Incidence at least 2% and Occurring More Frequently (greater than or equal to 2%) in the 100 mg Twice Daily Group than on Placebo) Adverse Reactions Placebo (N=973) Cilostazol 50 mg twice daily (N=303) Cilostazol 100 mg twice daily (N=998) Headache 14% 27% 34% Diarrhea 7% 12% 19% Abnormal stools 4% 12% 15% Palpitation 1% 5% 10% Dizziness 6% 9% 10% Pharyngitis 7% 7% 10% Infection 8% 14% 10% Peripheral edema 4% 9% 7% Rhinitis 5% 12% 7% Dyspepsia 4% 6% 6% Abdominal pain 3% 4% 5% Tachycardia 1% 4% 4% Less frequent clinical significant adverse reactions (less than 2%) that were experienced by patients treated with cilostazol 50 mg twice daily or 100 mg twice daily in the eight controlled clinical trials and that occurred at a frequency in the 100 mg twice daily group greater than in the placebo group are listed below. Body as a whole Fever, generalized edema, malaise Cardiovascular Atrial fibrillation, heart failure, myocardial infarction, nodal arrhythmia, supraventricular tachycardia, ventricular extrasystoles, ventricular tachycardia Digestive Anorexia, melena Hematologic and Lymphatic Anemia Metabolic and Nutritional Increased creatinine, hyperuricemia Nervous Insomnia Respiratory Epistaxis Skin and Appendages Urticaria Special Senses Conjunctivitis, retinal hemorrhage, tinnitus Urogenital Urinary frequency 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of cilostazol. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders Aplastic anemia, granulocytopenia, pancytopenia, bleeding tendency Cardiac disorders Torsade de pointes and QTc prolongation in patients with cardiac disorders (e.g., complete atrioventricular block, heart failure; and bradyarrythmia), angina pectoris. Gastrointestinal disorders Gastrointestinal hemorrhage, vomiting, flatulence, nausea General disorders and administration site conditions Pain, chest pain, hot flushes Hepatobiliary disorders Hepatic dysfunction/abnormal liver function tests, jaundice Immune system disorders Anaphylaxis, angioedema, and hypersensitivity Investigations Blood glucose increased, blood uric acid increased, increase in BUN (blood urea increased), blood pressure increase Nervous system disorders Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident, extradural hematoma and subdural hematoma Renal and urinary disorders Hematuria Respiratory, thoracic and mediastinal disorders Pulmonary hemorrhage, interstitial pneumonia Skin and subcutaneous tissue disorders Hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa), rash Vascular disorders Subacute stent thrombosis, hypertension."
      "warnings_and_cautions": [
        "5 WARNINGS AND PRECAUTIONS -Risks of tachycardia, palpitation, tachyarrhythmia or hypotension. Risks of exacerbations of angina pectoris or myocardial infarction in patients with a history of ischemic heart disease (5.1) -Risks of thrombocytopenia or leukopenia progressing to agranulocytosis--monitor platelets and white blood cell counts (5.2) -Avoid use in patients with hemostatic disorders or active pathologic bleeding (5.3) 5.1 Tachycardia Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension. The increase in heart rate associated with cilostazol is approximately 5 bpm to 7 bpm. Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction. 5.2 Hematologic Adverse Reactions Cases of thrombocytopenia or leukopenia progressing to agranulocytosis when cilostazol was not immediately discontinued have been reported. Agranulocytosis is reversible on discontinuation of cilostazol. Monitor platelets and white blood cell counts periodically. 5.3 Hemostatic Disorders or Active Pathologic Bleeding Cilostazol inhibits platelet aggregation in a reversible manner. Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding. Avoid use of cilostazol in these patients."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=6
Page 6 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "drug_interactions": [
        "Drug Interactions Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP34 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients currently treated with diltiazem, an inhibitor of CYP3A4 (see : ). Cilostazol does not, however, appear to cause increased blood levels of drug metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to CYP3A4 inhibition. CLINICAL PHARMACOLOGY Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions"
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2274 patients exposed to either 50 or 100 mg b.i.d. cilostazol (N=1301)or placebo (N=973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >=3% of patients treated with cilostazol 50 or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with cilostazol 50 mg b.i.d., 100 mg b.i.d, or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >=2% of patients treated with cilostazol 50 or 100 mg b.i.d., are shown in the table (below). Other events seen with an incidence of >=2%, but occurring in the placebo group at least as frequently as in the 100 mg b.i.d. group, were: asthenia, hypertension, vomiting, leg cramps, hyperesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. Most Commonly Reported AEs (Incidence >=2%) in Patients on Cilostazol 50 mg b.i.d. or 100 mg b.i.d. and Occurring at a Rate in the 100 mg b.i.d. Group Higher Than in Patients on Placebo Adverse Events (AEs) By Body System Cilostazol 50 mg b.i.d. (N=303) % Cilostazol 100 mg b.i.d. (N=998) % Placebo (N=973) % Body as a Whole Abdominal Pain 4 5 3 Back Pain 6 7 6 Headache 27 34 14 Infection 14 10 8 Cardiovascular Palpitation 5 10 1 Tachycardia 4 4 1 Digestive Abnormal Stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 Metabolic & Nutritional Peripheral Edema 9 7 4 Musculoskeletal Myalgia 2 3 2 Nervous Dizziness 9 10 6 Vertigo 3 1 1 Respiratory Cough Increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (<2%) that were experienced by patients exposed to cilostazol 50 mg b.i.d. or 100 mg b.i.d. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg b.i.d. group greater than in the placebo group, regardless of suspected drug relationship, are listed below. : Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal hemorrhage. Body as a whole : Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, hemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Cardiovascular : Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal hemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum hemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal hemorrhage, stomach ulcer, tongue edema. Digestive : Diabetes mellitus. Endocrine : Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Hemic and Lymphatic : Increased creatinine, gout, hyperlipemia, hyperuricemia. Metabolic and Nutritional : Arthralgia, bone pain, bursitis. Musculoskeletal : Anxiety, insomnia, neuralgia. Nervous : Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Respiratory : Dry skin, furunculosis, skin hypertrophy, urticaria. Skin and Appendages : Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye hemorrhage, retinal hemorrhage, tinnitus. Special Senses : Albuminuria, cystitis, urinary frequency, vaginal hemorrhage, vaginitis. Urogenital Post-Marketing Experience The following events have been reported spontaneously from worldwide post-marketing experience since the launch of cilostazol in the US. Agranulocytosis, aplastic anemia, granulocytopenia, thrombocytopenia, leukopenia, bleeding tendency Blood and Lymphatic System Disorders: Torsades de pointes, QTc prolongation Cardiac Disorders: (torsades de pointes and QTc prolongation occurred in patients with cardiac disorders, e.g. complete atrioventricular block, cardiac failure and bradyarrythmia, when treated with cilostazol. Cilostazol was used \"off label\" due to its positive chronotropic action) Gastrointestinal hemorrhage Gastrointestinal Disorders: Pain, chest pain, hot flushes General Disorders and Administration Site Conditions: Hepatic dysfunction/abnormal liver function tests, jaundice Hepatobiliary Disorders: Extradural hematoma and subdural hematoma Injury, Poisoning and Procedural Complications: Blood glucose increased, blood uric acid increased, platelet count decreased, white blood cell count decreased, increase in BUN (blood urea increased), blood pressure increase Investigations: Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident Nervous System Disorders: Pulmonary hemorrhage, interstitial pneumonia Respiratory, Thoracic and Mediastinal Disorders: Hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa) Skin and Subcutaneous Tissue Disorders: Subacute thrombosis (these cases of subacute thrombosis occurred in patients treated with aspirin and \"off label\" use of cilostazol for prevention of thrombotic complication after coronary stenting) Vascular Disorders:"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=7
Page 7 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "drug_interactions": [
        "Drug Interactions Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to CYP3A4 inhibition."
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2274 patients exposed to either 50 or 100 mg b.i.d. cilostazol (n = 1301) or placebo (n = 973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >= 3% of patients treated with cilostazol 50 or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with cilostazol 50 mg b.i.d., 100 mg b.i.d, or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >= 2% of patients treated with cilostazol 50 or 100 mg b.i.d., are shown in the table (below). Other events seen with an incidence of >= 2%, but occurring in the placebo group at least as frequently as in the 100 mg b.i.d. group were: asthenia, hypertension, vomiting, leg cramps, hyperesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. Most Commonly Reported AEs (Incidence >= 2%) in Patients on Cilostazol 50 mg b.i.d. or 100 mg b.i.d. and Occurring at a Rate in the 100 mg b.i.d. Group Higher Than in Patients on Placebo Adverse Events (AEs) by Body System Cilostazol 50 mg b.i.d. (N = 303) % Cilostazol 100 mg b.i.d. (N = 998) % Placebo (N = 973) % BODY AS A WHOLE Abdominal pain 4 5 3 Back pain 6 7 6 Headache 27 34 14 Infection 14 10 8 CARDIOVASCULAR Palpitation 5 10 1 Tachycardia 4 4 1 DIGESTIVE Abnormal stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 METABOLIC & NUTRITIONAL Peripheral edema 9 7 4 MUSCULO-SKELETAL Myalgia 2 3 2 NERVOUS Dizziness 9 10 6 Vertigo 3 1 1 RESPIRATORY Cough increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (< 2%) that were experienced by patients exposed to cilostazol 50 mg b.i.d. or 100 mg b.i.d. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg b.i.d. group greater than in the placebo group, regardless of suspected drug relationship, are listed below. Body as a whole: Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal hemorrhage. Cardiovascular: Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, hemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Digestive: Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal hemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum hemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal hemorrhage, stomach ulcer, tongue edema. Endocrine: Diabetes mellitus. Hemic and Lymphatic: Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Metabolic and Nutritional: Increased creatinine, gout, hyperlipemia, hyperuricemia. Musculoskeletal: Arthralgia, bone pain, bursitis. Nervous: Anxiety, insomnia, neuralgia. Respiratory: Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Skin and Appendages: Dry skin, furunculosis, skin hypertrophy, urticaria. Special Senses: Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye hemorrhage, retinal hemorrhage, tinnitus. Urogenital: Albuminuria, cystitis, urinary frequency, vaginal hemorrhage, vaginitis. Postmarketing Experience The following events have been reported spontaneously from worldwide postmarketing experience since launch of cilostazol in the U.S. Blood and lymphatic system disorders: Agranulocytosis, aplastic anemia, granulocytopenia, thrombocytopenia, leukopenia, bleeding tendency Cardiac disorders: Torsade de pointes, QTc prolongation (t orsade de pointes and QTc prolongation occurred in patients with cardiac disorders, e.g., complete atrioventricular block, cardiac failure and bradyarrythmia, when treated with cilostazol. Cilostazol was used "off label" due to its positive chronotropic action) Gastrointestinal disorders: Gastrointestinal hemorrhage General disorders and administration site conditions: Pain, chest pain, hot flushes Hepatobiliary disorders: Hepatic dysfunction/abnormal liver function tests, jaundice Injury, poisoning and procedural complications: Extradural hematoma and subdural hematoma Investigations: Blood glucose increased, blood uric acid increased, platelet count decreased, white blood cell count decreased, increase in BUN (blood urea increased), blood pressure increase Nervous system disorders: Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident Respiratory, thoracic and mediastinal disorders: Pulmonary hemorrhage, interstitial pneumonia Skin and subcutaneous tissue disorders: Hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa) Vascular disorders: Subacute thrombosis (these cases of subacute thrombosis occurred in patients treated with aspirin and "off label" use of cilostazol for prevention of thrombotic complication after coronary stenting)"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=8
Page 8 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "drug_interactions": [
        "Drug Interactions Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to CYP3A4 inhibition."
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2274 patients exposed to either 50 or 100 mg b.i.d. cilostazol (n = 1301) or placebo (n = 973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >= 3% of patients treated with cilostazol 50 or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with cilostazol 50 mg b.i.d., 100 mg b.i.d, or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >= 2% of patients treated with cilostazol 50 or 100 mg b.i.d., are shown in the table (below). Other events seen with an incidence of >= 2%, but occurring in the placebo group at least as frequently as in the 100 mg b.i.d. group were: asthenia, hypertension, vomiting, leg cramps, hyperesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. Most Commonly Reported AEs (Incidence >= 2%) in Patients on Cilostazol 50 mg b.i.d. or 100 mg b.i.d. and Occurring at a Rate in the 100 mg b.i.d. Group Higher Than in Patients on Placebo Adverse Events (AEs) by Body System Cilostazol 50 mg b.i.d. (N = 303) % Cilostazol 100 mg b.i.d. (N = 998) % Placebo (N = 973) % BODY AS A WHOLE Abdominal pain 4 5 3 Back pain 6 7 6 Headache 27 34 14 Infection 14 10 8 CARDIOVASCULAR Palpitation 5 10 1 Tachycardia 4 4 1 DIGESTIVE Abnormal stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 METABOLIC & NUTRITIONAL Peripheral edema 9 7 4 MUSCULO-SKELETAL Myalgia 2 3 2 NERVOUS Dizziness 9 10 6 Vertigo 3 1 1 RESPIRATORY Cough increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (< 2%) that were experienced by patients exposed to cilostazol 50 mg b.i.d. or 100 mg b.i.d. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg b.i.d. group greater than in the placebo group, regardless of suspected drug relationship, are listed below. Body as a whole: Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal hemorrhage. Cardiovascular: Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, hemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Digestive: Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal hemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum hemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal hemorrhage, stomach ulcer, tongue edema. Endocrine: Diabetes mellitus. Hemic and Lymphatic: Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Metabolic and Nutritional: Increased creatinine, gout, hyperlipemia, hyperuricemia. Musculoskeletal: Arthralgia, bone pain, bursitis. Nervous: Anxiety, insomnia, neuralgia. Respiratory: Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Skin and Appendages: Dry skin, furunculosis, skin hypertrophy, urticaria. Special Senses: Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye hemorrhage, retinal hemorrhage, tinnitus. Urogenital: Albuminuria, cystitis, urinary frequency, vaginal hemorrhage, vaginitis. Postmarketing Experience The following events have been reported spontaneously from worldwide postmarketing experience since the launch of cilostazol in the U.S. Blood and lymphatic system disorders: Agranulocytosis, aplastic anemia, granulocytopenia, thrombocytopenia, leukopenia, bleeding tendency Cardiac disorders: Torsade de pointes, QTc prolongation (t orsade de pointes and QTc prolongation occurred in patients with cardiac disorders, e.g., complete atrioventricular block, cardiac failure and bradyarrythmia, when treated with cilostazol. Cilostazol was used "off label" due to its positive chronotropic action) Gastrointestinal disorders: Gastrointestinal hemorrhage General disorders and administration site conditions: Pain, chest pain, hot flushes Hepatobiliary disorders: Hepatic dysfunction/abnormal liver function tests, jaundice Injury, poisoning and procedural complications: Extradural hematoma and subdural hematoma Investigations: Blood glucose increased, blood uric acid increased, platelet count decreased, white blood cell count decreased, increase in BUN (blood urea increased), blood pressure increase Nervous system disorders: Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident Respiratory, thoracic and mediastinal disorders: Pulmonary hemorrhage, interstitial pneumonia Skin and subcutaneous tissue disorders: Hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa) Vascular disorders: Subacute thrombosis (these cases of subacute thrombosis occurred in patients treated with aspirin and "off label" use of cilostazol for prevention of thrombotic complication after coronary stenting)"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=9
Page 9 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "cilostazol"
 
      "drug_interactions": [
        "Drug Interactions Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (seeCLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to CYP3A4 inhibition."
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2274 patients exposed to either 50 or 100 mg b.i.d. cilostazol (n=1301) or placebo (n=973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >= 3% of patients treated with cilostazol 50 or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with cilostazol 50 mg b.i.d., 100 mg b.i.d, or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >= 2% of patients treated with cilostazol 50 or 100 mg b.i.d., are shown in the table (below). Other events seen with an incidence of >= 2%, but occurring in the placebo group at least as frequently as in the 100 mg b.i.d. group were: asthenia, hypertension, vomiting, leg cramps, hyperesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. Most Commonly Reported AEs (Incidence >=2%) in Patients on Cilostazol 50 mg b.i.d. or 100 mg b.i.d. and Occurring at a Rate in the 100 mg b.i.d. Group Higher Than in Patients on Placebo Adverse Events (AEs) by Body System Cilostazol 50 mg b.i.d. (N=303) % Cilostazol 100 mg b.i.d. (N=998) % Placebo (N=973) % BODY AS A WHOLE Abdominal pain 4 5 3 Back pain 6 7 6 Headache 27 34 14 Infection 14 10 8 CARDIOVASCULAR Palpitation 5 10 1 Tachycardia 4 4 1 DIGESTIVE Abnormal stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 METABOLIC & NUTRITIONAL Peripheral edema 9 7 4 MUSCULO-SKELETAL Myalgia 2 3 2 NERVOUS Dizziness 9 10 6 Vertigo 3 1 1 RESPIRATORY Cough increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (<2%) that were experienced by patients exposed to cilostazol 50 mg b.i.d. or 100 mg b.i.d. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg b.i.d. group greater than in the placebo group, regardless of suspected drug relationship, are listed below. Body As a Whole Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal hemorrhage. Cardiovascular Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, hemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Digestive Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal hemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum hemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal hemorrhage, stomach ulcer, tongue edema. Endocrine Diabetes mellitus. Hemic and Lymphatic Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Metabolic and Nutritional Increased creatinine, gout, hyperlipemia, hyperuricemia. Musculoskeletal Arthralgia, bone pain, bursitis. Nervous Anxiety, insomnia, neuralgia. Respiratory Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Skin and Appendages Dry skin, furunculosis, skin hypertrophy, urticaria. Special Senses Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye hemorrhage, retinal hemorrhage, tinnitus. Urogenital Albuminuria, cystitis, urinary frequency, vaginal hemorrhage, vaginitis. Post-Marketing Experience The following events have been reported spontaneously from worldwide post-marketing experience since the launch of cilostazol in the US. - Blood and lymphatic system disorders - agranulocytosis, aplastic anemia, granulocytopenia, thrombocytopenia, leukopenia, bleeding tendency - Cardiac disorders - Torsades de pointes, QTc prolongation (Torsades de pointes and QTc prolongation occurred in patients with cardiac disorders, e.g. complete atrioventricular block, cardiac failure and bradyarrythmia, when treated with cilostazol. Cilostazol was used "off label" due to its positive chronotropic action.) - Gastrointestinal disorders - gastrointestinal haemorrhage - General disorders and administration site conditions - pain, chest pain, hot flushes - Hepatobiliary disorders - hepatic dysfunction/abnormal liver function tests, jaundice - Injury, poisoning and procedural complications - extradural haematoma and subdural haematoma - Investigations - blood glucose increased, blood uric acid increased, platelet count decreased, white blood cell count decreased, increase in BUN (blood urea increased), blood pressure increase - Nervous system disorders - intracranial haemorrhage, cerebral haemorrhage, cerebrovascular accident - Respiratory, thoracic and mediastinal disorders - pulmonary haemorrhage, interstitial pneumonia - Skin and subcutaneous tissue disorders - haemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa) - Vascular disorders - subacute thrombosis (These cases of subacute thrombosis occurred in patients treated with aspirin and "off label" use of cilostazol for prevention of thrombotic complication after coronary stenting.)"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=10
Page 10 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "drug_interactions": [
        "Drug Interactions: Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to CYP3A4 inhibition."
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2274 patients exposed to either 50 or 100 mg b.i.d. cilostazol tablets (n=1301) or placebo (n=973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >= 3% of patients treated with cilostazol 50 or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with cilostazol 50 mg b.i.d., 100 mg b.i.d, or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >= 2% of patients treated with cilostazol 50 or 100 mg b.i.d., are shown in the table below. Other events seen with an incidence of >= 2%, but occurring in the placebo group at least as frequently as in the 100 mg b.i.d. group were: asthenia, hypertension, vomiting, leg cramps, hypesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. Most Commonly Reported AEs (Incidence >=2%) in Patients on Cilostazol (CIL) 50 mg b.i.d. or 100 mg b.i.d. and Occurring at a Rate in the 100 mg b.i.d. Group Higher Than in Patients on Placebo Adverse Events (AEs) by Body System CIL 50 mg b.i.d. (N=303) % CIL 100 mg b.i.d. (N=998) % Placebo (N=973) % BODY AS A WHOLE Abdominal pain 4 5 3 Back pain 6 7 6 Headache 27 34 14 Infection 14 10 8 CARDIOVASCULAR Palpitation 5 10 1 Tachycardia 4 4 1 DIGESTIVE Abnormal stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 METABOLIC & NUTRITIONAL Peripheral edema 9 7 4 MUSCULO-SKELETAL Myalgia 2 3 2 NERVOUS Dizziness 9 10 6 Vertigo 3 1 1 RESPIRATORY Cough increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (< 2%) that were experienced by patients exposed to cilostazol 50 mg b.i.d. or 100 mg b.i.d. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg b.i.d. group greater than in the placebo group, regardless of suspected drug relationship, are listed below. Body as a whole: Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal hemorrhage. Cardiovascular: Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, hemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Digestive: Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal hemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum hemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal hemorrhage, stomach ulcer, tongue edema. Endocrine: Diabetes mellitus. Hemic and Lymphatic: Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Metabolic and Nutritional: Increased creatinine, gout, hyperlipemia, hyperuricemia. Musculoskeletal: Arthralgia, bone pain, bursitis. Nervous: Anxiety, insomnia, neuralgia. Respiratory: Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Skin and Appendages: Dry skin, furunculosis, skin hypertrophy, urticaria. Special Senses: Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye hemorrhage, retinal hemorrhage, tinnitus. Urogenital: Albuminuria, cystitis, urinary frequency, vaginal hemorrhage, vaginitis. Postmarketing Experience The following events have been reported spontaneously from worldwide postmarketing experience since the launch of cilostazol in the U.S. Blood and lymphatic system disorders: - Agranulocytosis, aplastic anemia, granulocytopenia, thrombocytopenia, leukopenia, bleeding tendency Cardiac disorders: - Torsades de pointes, QTc prolongation (Torsades de pointes and QTc prolongation occurred in patients with cardiac disorders, e.g. complete atrioventricular block, cardiac failure and bradyarrythmia, when treated with cilostazol. Cilostazol was used "off label" due to its positive chronotropic action.) Gastrointestinal disorders: - Gastrointestinal hemorrhage General disorders and administration site conditions: - Pain, chest pain, hot flushes Hepatobiliary disorders: - Hepatic dysfunction/abnormal liver function tests, jaundice Injury, poisoning and procedural complications: - Extradural hematoma and subdural hematoma Investigations: - Blood glucose increased, blood uric acid increased, platelet count decreased, white blood cell count decreased, increase in BUN (blood urea increased), blood pressure increase Nervous system disorders: - Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident Respiratory, thoracic and mediastinal disorders: - Pulmonary hemorrhage, interstitial pneumonia Skin and subcutaneous tissue disorders: - Hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa) Vascular disorders: - Subacute thrombosis (These cases of subacute thrombosis occurred in patients treated with aspirin and "off label" use of cilostazol for prevention of thrombotic complication after coronary stenting.)"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=11
Page 11 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "drug_interactions": [
        "Drug Interactions Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP34 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients currently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY : Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions). Cilostazol does not, however, appear to cause increased blood levels of drug metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to CYP3A4 inhibition."
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2274 patients exposed to either 50 or 100 mg b.i.d. cilostazol (N=1301)or placebo (N=973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >=3% of patients treated with cilostazol 50 or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with cilostazol 50 mg b.i.d., 100 mg b.i.d, or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >=2% of patients treated with cilostazol 50 or 100 mg b.i.d., are shown in the table (below). Other events seen with an incidence of >=2%, but occurring in the placebo group at least as frequently as in the 100 mg b.i.d. group, were: asthenia, hypertension, vomiting, leg cramps, hyperesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. Most Commonly Reported AEs (Incidence >=2%) in Patients on Cilostazol 50 mg b.i.d. or 100 mg b.i.d. and Occurring at a Rate in the 100 mg b.i.d. Group Higher Than in Patients on Placebo Adverse Events (AEs) By Body System Cilostazol 50 mg b.i.d. (N=303) % Cilostazol 100 mg b.i.d. (N=998) % Placebo (N=973) % Body as a Whole Abdominal Pain 4 5 3 Back Pain 6 7 6 Headache 27 34 14 Infection 14 10 8 Cardiovascular Palpitation 5 10 1 Tachycardia 4 4 1 Digestive Abnormal Stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 Metabolic & Nutritional Peripheral Edema 9 7 4 Musculoskeletal Myalgia 2 3 2 Nervous Dizziness 9 10 6 Vertigo 3 1 1 Respiratory Cough Increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (<2%) that were experienced by patients exposed to cilostazol 50 mg b.i.d. or 100 mg b.i.d. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg b.i.d. group greater than in the placebo group, regardless of suspected drug relationship, are listed below. Body as a whole: Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal hemorrhage. Cardiovascular: Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, hemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Digestive: Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal hemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum hemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal hemorrhage, stomach ulcer, tongue edema. Endocrine: Diabetes mellitus. Hemic and Lymphatic: Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Metabolic and Nutritional: Increased creatinine, gout, hyperlipemia, hyperuricemia. Musculoskeletal: Arthralgia, bone pain, bursitis. Nervous: Anxiety, insomnia, neuralgia. Respiratory: Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Skin and Appendages: Dry skin, furunculosis, skin hypertrophy, urticaria. Special Senses: Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye hemorrhage, retinal hemorrhage, tinnitus. Urogenital: Albuminuria, cystitis, urinary frequency, vaginal hemorrhage, vaginitis. Post-Marketing Experience The following events have been reported spontaneously from worldwide post-marketing experience since the launch of cilostazol in the US. Blood and Lymphatic System Disorders: Agranulocytosis, aplastic anemia, granulocytopenia, thrombocytopenia, leukopenia, bleeding tendency Cardiac Disorders: Torsades de pointes, QTc prolongation (torsades de pointes and QTc prolongation occurred in patients with cardiac disorders, e.g. complete atrioventricular block, cardiac failure and bradyarrythmia, when treated with cilostazol. Cilostazol was used \"off label\" due to its positive chronotropic action) Gastrointestinal Disorders: Gastrointestinal hemorrhage General Disorders and Administration Site Conditions: Pain, chest pain, hot flushes Hepatobiliary Disorders: Hepatic dysfunction/abnormal liver function tests, jaundice Injury, Poisoning and Procedural Complications: Extradural hematoma and subdural hematoma Investigations: Blood glucose increased, blood uric acid increased, platelet count decreased, white blood cell count decreased, increase in BUN (blood urea increased), blood pressure increase Nervous System Disorders: Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident Respiratory, Thoracic and Mediastinal Disorders: Pulmonary hemorrhage, interstitial pneumonia Skin and Subcutaneous Tissue Disorders: Hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa) Vascular Disorders: Subacute thrombosis (these cases of subacute thrombosis occurred in patients treated with aspirin and \"off label\" use of cilostazol for prevention of thrombotic complication after coronary stenting)"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=12
Page 12 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "cilostazol"
 
      "drug_interactions": [
        "Drug Interactions Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (seeCLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to CYP3A4 inhibition."
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2274 patients exposed to either 50 or 100 mg b.i.d. cilostazol (n=1301) or placebo (n=973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >= 3% of patients treated with cilostazol 50 or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with cilostazol 50 mg b.i.d., 100 mg b.i.d, or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >= 2% of patients treated with cilostazol 50 or 100 mg b.i.d., are shown in the table (below). Other events seen with an incidence of >= 2%, but occurring in the placebo group at least as frequently as in the 100 mg b.i.d. group were: asthenia, hypertension, vomiting, leg cramps, hyperesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. Most Commonly Reported AEs (Incidence >=2%) in Patients on Cilostazol 50 mg b.i.d. or 100 mg b.i.d. and Occurring at a Rate in the 100 mg b.i.d. Group Higher Than in Patients on Placebo Adverse Events (AEs) by Body System Cilostazol 50 mg b.i.d. (N=303) % Cilostazol 100 mg b.i.d. (N=998) % Placebo (N=973) % BODY AS A WHOLE Abdominal pain 4 5 3 Back pain 6 7 6 Headache 27 34 14 Infection 14 10 8 CARDIOVASCULAR Palpitation 5 10 1 Tachycardia 4 4 1 DIGESTIVE Abnormal stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 METABOLIC & NUTRITIONAL Peripheral edema 9 7 4 MUSCULO-SKELETAL Myalgia 2 3 2 NERVOUS Dizziness 9 10 6 Vertigo 3 1 1 RESPIRATORY Cough increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (<2%) that were experienced by patients exposed to cilostazol 50 mg b.i.d. or 100 mg b.i.d. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg b.i.d. group greater than in the placebo group, regardless of suspected drug relationship, are listed below. Body As a Whole Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal hemorrhage. Cardiovascular Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, hemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Digestive Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal hemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum hemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal hemorrhage, stomach ulcer, tongue edema. Endocrine Diabetes mellitus. Hemic and Lymphatic Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Metabolic and Nutritional Increased creatinine, gout, hyperlipemia, hyperuricemia. Musculoskeletal Arthralgia, bone pain, bursitis. Nervous Anxiety, insomnia, neuralgia. Respiratory Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Skin and Appendages Dry skin, furunculosis, skin hypertrophy, urticaria. Special Senses Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye hemorrhage, retinal hemorrhage, tinnitus. Urogenital Albuminuria, cystitis, urinary frequency, vaginal hemorrhage, vaginitis. Post-Marketing Experience The following events have been reported spontaneously from worldwide post-marketing experience since the launch of cilostazol in the US. Blood and lymphatic system disorders - agranulocytosis, aplastic anemia, granulocytopenia, thrombocytopenia, leukopenia, bleeding tendency Cardiac disorders - Torsades de pointes, QTc prolongation (Torsades de pointes and QTc prolongation occurred in patients with cardiac disorders, e.g. complete atrioventricular block, cardiac failure and bradyarrythmia, when treated with cilostazol. Cilostazol was used "off label" due to its positive chronotropic action.) Gastrointestinal disorders - gastrointestinal haemorrhage General disorders and administration site conditions - pain, chest pain, hot flushes Hepatobiliary disorders - hepatic dysfunction/abnormal liver function tests, jaundice Injury, poisoning and procedural complications - extradural haematoma and subdural haematoma Investigations - blood glucose increased, blood uric acid increased, platelet count decreased, white blood cell count decreased, increase in BUN (blood urea increased), blood pressure increase Nervous system disorders - intracranial haemorrhage, cerebral haemorrhage, cerebrovascular accident Respiratory, thoracic and mediastinal disorders - pulmonary haemorrhage, interstitial pneumonia Skin and subcutaneous tissue disorders - haemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa) Vascular disorders - subacute thrombosis (These cases of subacute thrombosis occurred in patients treated with aspirin and "off label" use of cilostazol for prevention of thrombotic complication after coronary stenting.)"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=13
Page 13 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "drug_interactions": [
        "Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions Cilostazol could have pharmacodynamic interactions with other inhibitors of platelet function and pharmacokinetic interactions because of effects of other drugs on its metabolism by CYP3A4 or CYP2C19. A reduced dose of cilostazol should be considered when taken concomitantly with CYP3A4 or CYP2C19 inhibitors. Cilostazol does not appear to inhibit CYP3A4 (see Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions, Lovastatin ). Aspirin Short-term (<= 4 days) coadministration of aspirin with cilostazol increased the inhibition of ADP-induced ex vivo platelet aggregation by 22% to 37% when compared to either aspirin or cilostazol alone. Short-term (<= 4 days) coadministration of aspirin with cilostazol increased the inhibition of arachidonic acid-induced ex vivo platelet aggregation by 20% compared to cilostazol alone and by 48% compared to aspirin alone. However, short-term coadministration of aspirin with cilostazol had no clinically significant impact on PT, aPTT, or bleeding time compared to aspirin alone. Effects of long-term coadministration in the general population are unknown. In eight randomized, placebo-controlled, double-blind clinical trials, aspirin was coadministered with cilostazol to 201 patients. The most frequent doses and mean durations of aspirin therapy were 75 to 81 mg daily for 137 days (107 patients) and 325 mg daily for 54 days (85 patients). There was no apparent increase in incidence of hemorrhagic adverse effects in patients taking cilostazol and aspirin compared to patients taking placebo and equivalent doses of aspirin. Warfarin The cytochrome P-450 isoenzymes involved in the metabolism of R-warfarin are CYP3A4, CYP1A2, and CYP2C19, and in the metabolism of S-warfarin, CYP2C9. Cilostazol did not inhibit either the metabolism or the pharmacologic effects (PT, aPTT, bleeding time, or platelet aggregation) of R- and S-warfarin after a single 25 mg dose of warfarin. The effect of concomitant multiple dosing of warfarin and cilostazol on the pharmacokinetics and pharmacodynamics of both drugs is unknown. Clopidogrel Multiple doses of clopidogrel do not significantly increase steady state plasma concentrations of cilostazol. Inhibitors of CYP3A4 Strong inhibitors of CY3A4 A priming dose of ketoconazole 400 mg (a strong inhibitor of CYP3A4), was given one day prior to coadministration of single doses of ketoconazole 400 mg and cilostazol 100 mg. This regimen increased cilostazol Cmax by 94% and AUC by 117%. Other strong inhibitors of CYP3A4, such as itraconazole, fluconazole, miconazole, fluvoxamine, fluoxetine, nefazodone, and sertraline, would be expected to have a similar effect (see DOSAGE AND ADMINISTRATION). Moderate inhibitors of CYP3A4 Erythromycin and other macrolide antibiotics: Erythromycin is a moderately strong inhibitor of CYP3A4. Coadministration of erythromycin 500 mg q8h with a single dose of cilostazol 100 mg increased cilostazol Cmax by 47% and AUC by 73%. Inhibition of cilostazol metabolism by erythromycin increased the AUC of 4'-trans-hydroxy-cilostazol by 141%. Other macrolide antibiotics (e.g., clarithromycin), but not all (e.g., azithromycin), would be expected to have a similar effect (see DOSAGE AND ADMINISTRATION). Diltiazem: Diltiazem 180 mg decreased the clearance of cilostazol by ~ 30%. Cilostazol Cmax increased ~ 30% and AUC increased ~ 40% (see DOSAGE AND ADMINISTRATION). Grapefruit Juice: Grapefruit juice increased the Cmax of cilostazol by ~ 50%, but had no effect on AUC. Inhibitors of CYP2C19 Omeprazole Coadministration of omeprazole did not significantly affect the metabolism of cilostazol, but the systemic exposure to 3,4-dehydro-cilostazol was increased by 69%, probably the result of omeprazole's potent inhibition of CYP2C19 (see DOSAGE AND ADMINISTRATION). Quinidine Concomitant administration of quinidine with a single dose of cilostazol 100 mg did not alter cilostazol pharmacokinetics. Lovastatin The concomitant administration of lovastatin with cilostazol decreases cilostazol Css, max and AUC by 15%. There is also a decrease, although nonsignificant, in cilostazol metabolite concentrations. Coadministration of cilostazol with lovastatin increases lovastatin and -hydroxi lovastatin AUC approximately 70%. This is most likely clinically insignificant.",
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2274 patients exposed to either 50 or 100 mg b.i.d. cilostazol (n = 1301) or placebo (n = 973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >= 3% of patients treated with cilostazol 50 or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with cilostazol 50 mg b.i.d., 100 mg b.i.d, or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >= 2% of patients treated with cilostazol 50 or 100 mg b.i.d., are shown in the table (below). Other events seen with an incidence of >= 2%, but occurring in the placebo group at least as frequently as in the 100 mg b.i.d. group were: asthenia, hypertension, vomiting, leg cramps, hypesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. Most Commonly Reported AEs (Incidence >= 2%) in Patients on Cilostazol 50 mg b.i.d. or 100 mg b.i.d. and Occurring at a Rate in the 100 mg b.i.d. Group Higher Than in Patients on Placebo Adverse Events (AEs) by Body System Cilostazol 50 mg b.i.d. (N = 303) % Cilostazol 100 mg b.i.d. (N = 998) % Placebo (N = 973) % BODY AS A WHOLE Abdominal pain 4 5 3 Back pain 6 7 6 Headache 27 34 14 Infection 14 10 8 CARDIOVASCULAR Palpitation 5 10 1 Tachycardia 4 4 1 DIGESTIVE Abnormal stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 METABOLIC & NUTRITIONAL Peripheral edema 9 7 4 MUSCULO-SKELETAL Myalgia 2 3 2 NERVOUS Dizziness 9 10 6 Vertigo 3 1 1 RESPIRATORY Cough increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (< 2%) that were experienced by patients exposed to cilostazol 50 mg b.i.d. or 100 mg b.i.d. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg b.i.d. group greater than in the placebo group, regardless of suspected drug relationship, are listed below. Body as a whole: Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal hemorrhage. Cardiovascular: Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, hemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Digestive: Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal hemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum hemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal hemorrhage, stomach ulcer, tongue edema. Endocrine: Diabetes mellitus. Hemic and Lymphatic: Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Metabolic and Nutritional: Increased creatinine, gout, hyperlipemia, hyperuricemia. Musculoskeletal: Arthralgia, bone pain, bursitis. Nervous: Anxiety, insomnia, neuralgia. Respiratory: Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Skin and Appendages: Dry skin, furunculosis, skin hypertrophy, urticaria. Special Senses: Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye hemorrhage, retinal hemorrhage, tinnitus. Urogenital: Albuminuria, cystitis, urinary frequency, vaginal hemorrhage, vaginitis. Postmarketing Experience The following events have been reported spontaneously from worldwide postmarketing experience since launch of cilostazol in the U.S. Blood and lymphatic system disorders: Agranulocytosis, aplastic anemia, granulocytopenia, thrombocytopenia, leukopenia, bleeding tendency Cardiac disorders: Torsade de pointes, QTc prolongation (t orsade de pointes and QTc prolongation occurred in patients with cardiac disorders, e.g., complete atrioventricular block, cardiac failure and bradyarrythmia, when treated with cilostazol. Cilostazol was used "off label" due to its positive chronotropic action) Gastrointestinal disorders: Gastrointestinal hemorrhage General disorders and administration site conditions: Pain, chest pain, hot flushes Hepatobiliary disorders: Hepatic dysfunction/abnormal liver function tests, jaundice Injury, poisoning and procedural complications: Extradural hematoma and subdural hematoma Investigations: Blood glucose increased, blood uric acid increased, platelet count decreased, white blood cell count decreased, increase in BUN (blood urea increased), blood pressure increase Nervous system disorders: Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident Respiratory, thoracic and mediastinal disorders: Pulmonary hemorrhage, interstitial pneumonia Skin and subcutaneous tissue disorders: Hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa) Vascular disorders: Subacute thrombosis (these cases of subacute thrombosis occurred in patients treated with aspirin and "off label" use of cilostazol for prevention of thrombotic complication after coronary stenting)"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=14
Page 14 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2274 patients exposed to either 50 or 100 mg twice daily cilostazol (n=1301) or placebo (n=973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >=3% of patients treated with cilostazol 50 or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with cilostazol 50 mg twice daily, 100 mg twice daily, or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >=2% of patients treated with cilostazol 50 or 100 mg twice daily, are shown in the table (below). Other events seen with an incidence of >=2%, but occurring in the placebo group at least as frequently as in the 100 mg twice daily group were: asthenia, hypertension, vomiting, leg cramps, hypesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. Most Commonly Reported AEs (Incidence >=2%) in Patients on Cilostazol 50 mg Twice Daily or 100 mg Twice Daily and Occurring at a Rate in the 100 mg Twice Daily Group Higher Than in Patients on Placebo Adverse Events (AEs) By Body System Cilostazol 50 mg twice daily (N=303) % Cilostazol 100 mg twice daily (N=998) % Placebo (N=973) % Body as a Whole Abdominal Pain 4 5 3 Back Pain 6 7 6 Headache 27 34 14 Infection 14 10 8 Cardiovascular Palpitation 5 10 1 Tachycardia 4 4 1 Digestive Abnormal Stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 Metabolic & Nutritional Peripheral Edema 9 7 4 Musculoskeletal Myalgia 2 3 2 Nervous Dizziness 9 10 6 Vertigo 3 1 1 Respiratory Cough Increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (<2%) that were experienced by patients exposed to cilostazol 50 mg twice daily or 100 mg twice daily in the eight controlled clinical trials and that occurred at a frequency in the 100 mg twice daily group greater than in the placebo group, regardless of suspected drug relationship, are listed below. Body as a whole: Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal haemorrhage. Cardiovascular: Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, haemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Digestive: Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal haemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum haemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal haemorrhage, stomach ulcer, tongue edema. Endocrine: Diabetes mellitus. Hemic and Lymphatic: Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Metabolic and Nutritional: Increased creatinine, gout, hyperlipemia, hyperuricemia. Musculoskeletal: Arthralgia, bone pain, bursitis. Nervous: Anxiety, insomnia, neuralgia. Respiratory: Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Skin and Appendages: Dry skin, furunculosis, skin hypertrophy, urticaria. Special Senses: Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye haemorrhage, retinal hemorrhage, tinnitus. Urogenital: Albuminuria, cystitis, urinary frequency, vaginal haemorrhage, vaginitis. Post-Marketing Experience The following adverse drug reactions (ADRs) have been reported worldwide since the launch of cilostazol in the US. - Blood and Lymphatic System Disorders: Agranulocytosis, aplastic anemia, granulocytopenia, thrombocytopenia, leukopenia, bleeding tendency - Cardiac Disorders: Torsades de pointes, QTc prolongation (torsades de pointes and QTc prolongation occurred in patients with cardiac disorders, e.g. complete atrioventricular block, cardiac failure and bradyarrythmia, when treated with cilostazol. Cilostazol was used \"off label\" due to its positive chronotropic action) - Gastrointestinal Disorders: Gastrointestinal haemorrhage - General Disorders and Administration Site Conditions: Pain, chest pain, hot flushes - Hepatobiliary Disorders: Hepatic dysfunction/abnormal liver function tests, jaundice - Injury, Poisoning and Procedural Complications: Extradural haematoma and subdural haematoma - Investigations: Blood glucose increased, blood uric acid increased, platelet count decreased, white blood cell count decreased, increase in BUN (blood urea increased), blood pressure increase - Nervous System Disorders: Intracranial haemorrhage, cerebral haemorrhage, cerebrovascular accident - Respiratory, Thoracic and Mediastinal Disorders: Pulmonary haemorrhage, interstitial pneumonia - Skin and Subcutaneous Tissue Disorders: Haemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa) - Vascular Disorders: Subacute thrombosis (these cases of subacute thrombosis occurred in patients treated with aspirin and \"off label\" use of cilostazol for prevention of thrombotic complication after coronary stenting)"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=15
Page 15 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "drug_interactions": [
        "7 DRUG INTERACTIONS - Strong and moderate CYP3A4 and CYP2C19 inhibitors: Increase exposure to cilostazol. Reduce cilostazol dose (2.2, 7.1) 7.1 Inhibitors of CYP3A4 or CYP2C19 Inhibitors of CYP3A4 Coadministration of strong (e.g., ketoconazole) and moderate (e.g., erythromycin, diltiazem and grapefruit juice) CYP3A4 inhibitors can increase exposure to cilostazol. Reduce cilostazol dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP3A4 [see Dosage and Administration ( 2.2) and Clinical Pharmacology (12.3)]. Inhibitors of CYP2C19 Coadministration with CYP2C19 inhibitors (e.g., omeprazole) increases systemic exposure of cilostazol active metabolites. Reduce cilostazol dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP2C19 [see Dosage and Administration ( 2.2) and Clinical Pharmacology (12.3)]."
      "adverse_reactions": [
        "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: - Patients with Heart Failure [see Boxed Warning] - Tachycardia [see Warnings and Precautions ( 5.1)] - Hematologic Adverse Reactions [see Warnings and Precautions ( 5.2 )] - Hemostatic Disorders or Active Pathologic Bleeding [see Warnings and Precautions ( 5.3)] Most common adverse reactions greater than or equal to 2% and at least twice that for placebo in patients on 100 mg twice daily are headache, diarrhea, abnormal stools, and palpitation (6.1) To report SUSPECTED ADVERSE REACTIONS, contact TEVA USA, PHARMACOVIGILANCE at 1-866-832-8537 or drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions were assessed in eight placebo-controlled clinical trials involving patients exposed to either 50 or 100 mg twice daily cilostazol (n = 1301) or placebo (n = 973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The most frequent adverse reaction resulting in discontinuation of therapy in more than 3% of patients treated with cilostazol was headache [50 mg twice daily (1.3%), 100 mg twice daily (3.5%) and placebo (0.3%)]. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most common adverse reactions, occurring in at least 2% of patients treated with cilostazol 50 or 100 mg twice daily, are shown in Table 1. Table 1: Most Common Adverse Reactions in Patients on Cilostazol 50 or 100 mg Twice Daily (Incidence at least 2% and Occurring More Frequently (>= 2%) in the 100 mg Twice Daily Group than on Placebo) Adverse Reactions Placebo (N = 973) Cilostazol 50 mg twice daily (N = 303) Cilostazol 100 mg twice daily (N = 998) Headache 14% 27% 34% Diarrhea 7% 12% 19% Abnormal stools 4% 12% 15% Palpitation 1% 5% 10% Dizziness 6% 9% 10% Pharyngitis 7% 7% 10% Infection 8% 14% 10% Peripheral edema 4% 9% 7% Rhinitis 5% 12% 7% Dyspepsia 4% 6% 6% Abdominal pain 3% 4% 5% Tachycardia 1% 4% 4% Less frequent clinical significant adverse reactions (less than 2%) that were experienced by patients treated with cilostazol 50 mg twice daily or 100 mg twice daily in the eight controlled clinical trials and that occurred at a frequency in the 100 mg twice daily group greater than in the placebo group are listed below. Body as a whole: fever, generalized edema, malaise Cardiovascular: atrial fibrillation, heart failure, myocardial infarction, nodal arrhythmia, supraventricular tachycardia, ventricular extrasystoles, ventricular tachycardia Digestive: anorexia, melena Hematologic and Lymphatic: anemia Metabolic and Nutritional: increased creatinine, hyperuricemia Nervous: insomnia Respiratory: epistaxis Skin and Appendages: urticaria Special Senses: conjunctivitis, retinal hemorrhage, tinnitus Urogenital: urinary frequency 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of cilostazol. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: Aplastic anemia, granulocytopenia, pancytopenia, bleeding tendency Cardiac disorders: Torsade de pointes and QTc prolongation in patients with cardiac disorders (e.g. complete atrioventricular block, heart failure; and bradyarrythmia), angina pectoris. Gastrointestinal disorders: Gastrointestinal hemorrhage, vomiting, flatulence, nausea General disorders and administration site conditions: Pain, chest pain, hot flushes Hepatobiliary disorders: Hepatic dysfunction/abnormal liver function tests, jaundice Immune system disorders: Anaphylaxis, angioedema, and hypersensitivity Investigations: Blood glucose increased, blood uric acid increased, increase in BUN (blood urea increased), blood pressure increase Nervous system disorders: Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident, extradural hematoma and subdural hematoma Renal and urinary disorders: Hematuria Respiratory, thoracic and mediastinal disorders: Pulmonary hemorrhage, interstitial pneumonia Skin and subcutaneous tissue disorders: Hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa), rash Vascular disorders: Subacute stent thrombosis, hypertension."
      "warnings_and_cautions": [
        "5 WARNINGS AND PRECAUTIONS -Risks of tachycardia, palpitation, tachyarrhythmia or hypotension. Risks of exacerbations of angina pectoris or myocardial infarction in patients with a history of ischemic heart disease (5.1) -Risks of thrombocytopenia or leukopenia progressing to agranulocytosis--monitor platelets and white blood cell counts (5.2) -Avoid use in patients with hemostatic disorders or active pathologic bleeding (5.3) 5.1 Tachycardia Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension. The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm. Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction. 5.2 Hematologic Adverse Reactions Cases of thrombocytopenia or leukopenia progressing to agranulocytosis when cilostazol was not immediately discontinued have been reported. Agranulocytosis is reversible on discontinuation of cilostazol. Monitor platelets and white blood cell counts periodically. 5.3 Hemostatic Disorders or Active Pathologic Bleeding Cilostazol inhibits platelet aggregation in a reversible manner. Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding. Avoid use of cilostazol in these patients."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=16
Page 16 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "drug_interactions": [
        "Drug Interactions Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to CYP3A4 inhibition."
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2274 patients exposed to either 50 or 100 mg b.i.d. cilostazol (n=1301) or placebo (n=973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >= 3% of patients treated with cilostazol 50 or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with cilostazol 50 mg b.i.d., 100 mg b.i.d. or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >= 2% of patients treated with cilostazol 50 or 100 mg b.i.d., are shown in the table below. Other events seen with an incidence of >= 2%, but occurring in the placebo group at least as frequently as in the 100 mg b.i.d. group were: asthenia, hypertension, vomiting, leg cramps, hypesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. Most Commonly Reported AEs (Incidence >=2%) in Patients on Cilostazol 50 mg b.i.d. or 100 mg b.i.d. and Occurring at a Rate in the 100 mg b.i.d. Group Higher Than in Patients on Placebo Adverse Events (AEs) by Body System Cilostazol 50 mg b.i.d. (N=303) % Cilostazol 100 mg b.i.d. (N=998) % Placebo (N=973) % BODY AS A WHOLE Abdominal pain 4 5 3 Back pain 6 7 6 Headache 27 34 14 Infection 14 10 8 CARDIOVASCULAR Palpitation 5 10 1 Tachycardia 4 4 1 DIGESTIVE Abnormal stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 METABOLIC & NUTRITIONAL Peripheral edema 9 7 4 MUSCULO-SKELETAL Myalgia 2 3 2 NERVOUS Dizziness 9 10 6 Vertigo 3 1 1 RESPIRATORY Cough increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (< 2%) that were experienced by patients exposed to cilostazol 50 mg b.i.d. or 100 mg b.i.d. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg b.i.d. group greater than in the placebo group, regardless of suspected drug relationship, are listed below. Body as a whole: Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal hemorrhage. Cardiovascular: Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, hemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Digestive: Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal hemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum hemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal hemorrhage, stomach ulcer, tongue edema. Endocrine: Diabetes mellitus. Hemic and Lymphatic: Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Metabolic and Nutritional:: Increased creatinine, gout, hyperlipemia, hyperuricemia. Musculoskeletal: Arthralgia, bone pain, bursitis. Nervous: Anxiety, insomnia, neuralgia. Respiratory: Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Skin and Appendages: Dry skin, furunculosis, skin hypertrophy, urticaria. Special Senses: Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye hemorrhage, retinal hemorrhage, tinnitus. Urogenital: Albuminuria, cystitis, urinary frequency, vaginal hemorrhage, vaginitis Post-Marketing Experience The following events have been reported spontaneously from worldwide post-marketing experience since launch of cilostazol in the US. - Blood and lymphatic system disorders: -Agranulocytosis, aplastic anemia, granulocytopenia, thrombocytopenia, leukopenia, bleeding tendency - Cardiac disorders: -Torsades de pointes, QTc prolongation (Torsades de pointes and QTc prolongation occurred in patients with cardiac disorders, e.g. complete atrioventricular block, cardiac failure and bradyarrythmia, when treated with cilostazol. Cilostazol was used "off label" due to its positive chronotropic action.) - Gastrointestinal disorders: -Gastrointestinal hemorrhage - General disorders and administration site conditions: -Pain, chest pain, hot flushes - Hepatobiliary disorders: -Hepatic dysfunction/abnormal liver function tests, jaundice - Injury, poisoning and procedural complications: -Extradural hematoma and subdural hematoma - Investigations : -Blood glucose increased, blood uric acid increased, platelet count decreased, white blood cell count decreased, increase in BUN (blood urea increased), blood pressure increase - Nervous system disorders: -Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident - Respiratory, thoracic and mediastinal disorders: -Pulmonary hemorrhage, interstitial pneumonia - Skin and subcutaneous tissue disorders: -Hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa) - Vascular disorders: -Subacute thrombosis (These cases of subacute thrombosis occurred in patients treated with aspirin and "off label" use of cilostazol for prevention of thrombotic complication after coronary stenting.)"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=17
Page 17 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "drug_interactions": [
        "Drug Interactions Since CILOSTAZOL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when CILOSTAZOL is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions). CILOSTAZOL does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to CYP3A4 inhibition."
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2274 patients exposed to either 50 or 100 mg b.i.d. CILOSTAZOL (n=1301) or placebo (n=973), with a median treatment duration of 127 days for patients on CILOSTAZOL and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >= 3% of patients treated with CILOSTAZOL 50 or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with CILOSTAZOL 50 mg b.i.d., 100 mg b.i.d, or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >= 2% of patients treated with CILOSTAZOL 50 or 100 mg b.i.d., are shown in the table (below). Other events seen with an incidence of >= 2%, but occurring in the placebo group at least as frequently as in the 100 mg b.i.d. group were: asthenia, hypertension, vomiting, leg cramps, hypesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. Most Commonly Reported AEs (Incidence >=2%) in Patients on CILOSTAZOL (CZL) 50 mg b.i.d. or 100 mg b.i.d. and Occuring at a Rate in the 100 mg b.i.d. Group Higher Than in Patients on Placebo Adverse Events (AEs) by Body System CZL 50 mg b.i.d. (N=303) % CZL 100 mg b.i.d. (N=998) % Placebo (N=973) % BODY AS A WHOLE Abdominal Pain 4 5 3 Back pain 6 7 6 Headache 27 34 14 Infection 14 10 8 CARDIOVASCULAR Palpitation 5 10 1 Tachycardia 4 4 1 DIGESTIVE Abnormal stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 METABOLIC & NUTRITIONAL Peripheral edema 9 7 4 MUSCULO-SKELETAL Myalgia 2 3 2 NERVOUS Dizziness 9 10 6 Vertigo 3 1 1 RESPIRATORY Cough increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (<2%) that were experienced by patients exposed to CILOSTAZOL 50 mg b.i.d. or 100 mg b.i.d. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg b.i.d. group greater than in the placebo group, regardless of suspected drug relationship, are listed below. Body as a whole: Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal haemorrhage. Cardiovascular: Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, haemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Digestive: Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal haemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum haemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal haemorrhage, stomach ulcer, tongue edema. Endocrine: Diabetes mellitus. Hemic and Lymphatic: Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Metabolic and Nutritional: Increased creatinine, gout, hyperlipemia, hyperuricemia. Musculoskeletal: Arthralgia, bone pain, bursitis. Nervous: Anxiety, insomnia, neuralgia. Respiratory: Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Skin and Appendages: Dry skin, furunculosis, skin hypertrophy, urticaria. Special Senses: Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye haemorrhage, retinal haemorrhage, tinnitus. Urogenital: Albuminuria, cystitis, urinary frequency, vaginal haemorrhage, vaginitis. Postmarketing Experience The following events have been reported spontaneously from worldwide postmarketing experience since the launch of cilostazol in the U.S. Blood and lymphatic system disorders: agranulocytosis, aplastic anemia, granulocytopenia, thrombocytopenia, leukopenia, bleeding tendency Cardiac disorders: Torsades de pointes, QTc prolongation (torsades de pointes and QTc prolongation occurred in patients with cardiac disorders, e.g. complete atrioventricular block, cardiac failure and bradyarrhythmia, when treated with cilostazol. Cilostazol was used \"off label\" due to its positive chronotropic action.) Gastrointestinal disorders: gastrointestinal haemorrhage General disorders and administration site conditions: pain, chest pain, hot flushes Hepatobiliary disorders: hepatic dysfunction/abnormal liver function tests, jaundice Injury, poisoning and procedural complications: extradural haematoma and subdural haematoma Investigations: blood glucose increased, blood uric acid increased, platelet count decreased, white blood cell count decreased, increase in BUN (blood urea increased), blood pressure increase Nervous system disorders: intracranial haemorrhage, cerebral haemorrhage, cerebrovascular accident Respiratory, thoracic and mediastinal disorders: pulmonary haemorrhage, interstitial pneumonia Skin and subcutaneous tissue disorders: haemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa) Vascular disorders: subacute thrombosis (These cases of subacute thrombosis occurred in patients treated with aspirin and \"off label\" use of cilostazol for prevention of thrombotic complication after coronary stenting.)"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=18
Page 18 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2,274 patients exposed to either 50 mg or 100 mg b.i.d. cilostazol (n=1,301) or placebo (n=973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >=3% of patients treated with cilostazol 50 mg or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5% and 0.3% in patients treated with cilostazol 50 mg b.i.d., 100 mg b.i.d. or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >=2% of patients treated with cilostazol 50 mg or 100 mg b.i.d., are shown in the table (below). Other events seen with an incidence of >=2% but, occurring in the placebo group at least as frequently as in the 100 mg b.i.d. group were: asthenia, hypertension, vomiting, leg cramps, hypesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis and bronchitis. Most Commonly Reported AEs (Incidence >= 2%) in Patients on Cilostazol Tablets 50 mg b.i.d . or 100 mg b.i.d . and Occurring at a Rate in the 100 mg b.i.d . Group Higher Than in Patients on Placebo Adverse Events (AEs) by Body System Cilostazol 50 mg b.i.d . (n=303) % Cilostazol 100 mg b.i.d . (n=998) % Placebo (n=973) % Body as a Whole Abdominal pain 4 5 3 Back pain 6 7 6 Headache 27 34 14 Infection 14 10 8 Cardiovascular Palpitation 5 10 1 Tachycardia 4 4 1 Digestive Abnormal stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 Metabolic & Nutritional Peripheral edema 9 7 4 Musculoskeletal Myalgia 2 3 2 Nervous Dizziness 9 10 6 Vertigo 3 1 1 Respiratory Cough increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (<2%) that were experienced by patients exposed to cilostazol 50 mg b.i.d. or 100 mg b.i.d. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg b.i.d. group greater than in the placebo group, regardless of suspected drug relationship, are listed below. Body as a Whole: Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal hemorrhage. Cardiovascular: Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, hemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Digestive: Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal hemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum hemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal hemorrhage, stomach ulcer, tongue edema. Endocrine: Diabetes mellitus. Hemic and Lymphatic: Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Metabolic and Nutritional: Increased creatinine, gout, hyperlipemia, hyperuricemia. Musculoskeletal: Arthralgia, bone pain, bursitis. Nervous: Anxiety, insomnia, neuralgia. Respiratory: Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Skin and Appendages: Dry skin, furunculosis, skin hypertrophy, urticaria. Special Senses: Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye hemorrhage, retinal hemorrhage, tinnitus. Urogenital: Albuminuria, cystitis, urinary frequency, vaginal hemorrhage, vaginitis. Postmarketing Experience The following events have been reported spontaneously from worldwide post-marketing experience since the launch of cilostazol in the U.S. - Blood and lymphatic system disorders: -Agranulocytosis, aplastic anemia, granulocytopenia, thrombocytopenia, leukopenia, bleeding tendency - Cardiac disorders: -Torsades de pointes, QTc prolongation ( torsades de pointes and QTc prolongation occurred in patients with cardiac disorders, e.g. complete atrioventricular block, cardiac failure and bradyarrythmia , when treated with cilostazol . Cilostazol was used "off label" due to its positive chronotropic action) - Gastrointestinal disorders: -Gastrointestinal hemorrhage - General disorders and administration site conditions: -Pain, chest pain, hot flushes - Hepatobiliary disorders: -Hepatic dysfunction/abnormal liver function tests, jaundice - Injury, poisoning and procedural complications: -Extradural hematoma and subdural hematoma - Investigations: -Blood glucose increased, blood uric acid increased, platelet count decreased, white blood cell count decreased, increase in BUN (blood urea increased), blood pressure increase - Nervous system disorders: -Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident - Respiratory, thoracic and mediastinal disorders: -Pulmonary hemorrhage, interstitial pneumonia - Skin and subcutaneous tissue disorders: -Hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa) - Vascular disorders: -Subacute thrombosis (these cases of subacute thrombosis occurred in patients treated with aspirin and "off label" use of cilostazol for prevention of thrombotic complication after coronary stenting)"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=19
Page 19 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "cilostazol"
 
      "drug_interactions": [
        "7 DRUG INTERACTIONS Strong and moderate CYP3A4 and CYP2C19 inhibitors: Increase exposure to cilostazol. Reduce cilostazol tablets dose (2.2, 7.1) 7.1 Inhibitors of CYP3A4 or CYP2C19 Inhibitors of CYP3A4 Coadministration of strong (e.g., ketoconazole) and moderate (e.g., erythromycin, diltiazem and grapefruit juice) CYP3A4 inhibitors can increase exposure to cilostazol. Reduce cilostazol dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP3A4 [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)]. Inhibitors of CYP2C19 Coadministration with CYP2C19 inhibitors (e.g., omeprazole) increases systemic exposure of cilostazol active metabolites. Reduce cilostazol dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP2C19 [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)]."
      "adverse_reactions": [
        "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: Patients with Heart Failure [see Boxed Warning] Tachycardia [see Warnings and Precautions (5.1)] Hematologic Adverse Reactions [see Warnings and Precautions (5.2)] Hemostatic Disorders or Active Pathologic Bleeding [see Warnings and Precautions (5.3)] Most common adverse reactions greater than or equal to 2% and at least twice that for placebo in patients on 100 mg twice daily are headache, diarrhea, abnormal stools, and palpitation (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Inc. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions were assessed in eight placebo-controlled clinical trials involving patients exposed to either 50 or 100 mg twice daily cilostazol tablets (n=1301) or placebo (n=973), with a median treatment duration of 127 days for patients on cilostazol tablets and 134 days for patients on placebo. The most frequent adverse reaction resulting in discontinuation of therapy in more than 3% of patients treated with cilostazol tablets was headache [50 mg twice daily (1.3%), 100 mg twice daily (3.5%) and placebo (0.3%)]. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol tablets (all doses) versus 0.1% for placebo. The most common adverse reactions, occurring in at least 2% of patients treated with cilostazol tablets 50 or 100 mg twice daily, are shown in Table 1. Table 1: Most Common Adverse Reactions in Patients on cilostazol tablets 50 or 100 mg Twice Daily (Incidence at least 2% and Occurring More Frequently (>= 2%) in the 100 mg Twice Daily Group than on Placebo) Adverse Reactions Placebo (N=973) Cilostazol tablets 50 mg twice daily (N=303) Cilostazol tablets 100 mg twice daily (N=998) Headache 14% 27% 34% Diarrhea 7% 12% 19% Abnormal stools 4% 12% 15% Palpitation 1% 5% 10% Dizziness 6% 9% 10% Pharyngitis 7% 7% 10% Infection 8% 14% 10% Peripheral edema 4% 9% 7% Rhinitis 5% 12% 7% Dyspepsia 4% 6% 6% Abdominal pain 3% 4% 5% Tachycardia 1% 4% 4% Less frequent clinical significant adverse reactions (less than 2%) that were experienced by patients treated with cilostazol 50 mg twice daily or 100 mg twice daily in the eight controlled clinical trials and that occurred at a frequency in the 100 mg twice daily group greater than in the placebo group are listed below. Body as a whole: fever, generalized edema, malaise Cardiovascular: atrial fibrillation, heart failure, myocardial infarction, nodal arrhythmia, supraventricular tachycardia, ventricular extrasystoles, ventricular tachycardia Digestive: anorexia, melena Hematologic and Lymphatic: anemia Metabolic and Nutritional: increased creatinine, hyperuricemia Nervous: insomnia Respiratory: epistaxis Skin and Appendages: urticaria Special Senses: conjunctivitis, retinal hemorrhage, tinnitus Urogenital: urinary frequency 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of cilostazol tablets. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: Aplastic anemia, granulocytopenia, pancytopenia, bleeding tendency Cardiac disorders: Torsade de pointes and QTc prolongation in patients with cardiac disorders (e.g. complete atrioventricular block, heart failure; and bradyarrythmia), angina pectoris. Gastrointestinal disorders: Gastrointestinal hemorrhage, vomiting, flatulence, nausea General disorders and administration site conditions: Pain, chest pain, hot flushes Hepatobiliary disorders: Hepatic dysfunction/abnormal liver function tests, jaundice Immune system disorders: Anaphylaxis, angioedema, and hypersensitivity Investigations: Blood glucose increased, blood uric acid increased, increase in BUN (blood urea increased), blood pressure increase Nervous system disorders: Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident, extradural hematoma and subdural hematoma Renal and urinary disorders: Hematuria Respiratory, thoracic and mediastinal disorders: Pulmonary hemorrhage, interstitial pneumonia Skin and subcutaneous tissue disorders: Hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa), rash Vascular disorders: Subacute stent thrombosis, hypertension."
      "warnings_and_cautions": [
        "5 WARNINGS AND PRECAUTIONS Risks of tachycardia, palpitation, tachyarrhythmia or hypotension. Risks of exacerbations of angina pectoris or myocardial infarction in patients with a history of ischemic heart disease (5.1) Risks of thrombocytopenia or leukopenia progressing to agranulocytosis-monitor platelets and white blood cell counts (5.2) Avoid use in patients with hemostatic disorders or active pathologic bleeding (5.3) 5.1 Tachycardia Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension. The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm. Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction. 5.2 Hematologic Adverse Reactions Cases of thrombocytopenia or leukopenia progressing to agranulocytosis when cilostazol was not immediately discontinued have been reported. Agranulocytosis is reversible on discontinuation of cilostazol. Monitor platelets and white blood cell counts periodically. 5.3 Hemostatic Disorders or Active Pathologic Bleeding Cilostazol inhibits platelet aggregation in a reversible manner. Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding. Avoid use of cilostazol tablets in these patients."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=20
Page 20 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2274 patients exposed to either 50 or 100 mg twice daily cilostazol (n=1301) or placebo (n=973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >= 3% of patients treated with cilostazol 50 or 100 mg twice daily was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with cilostazol 50 mg twice daily, 100 mg twice daily, or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >= 2% of patients treated with cilostazol 50 or 100 mg twice daily, and with a frequency higher than placebo, are shown in the table (below). Other events seen with an incidence of >= 2%, but occurring in the placebo group at least as frequently as in the 100 mg twice daily group were: asthenia, hypertension, vomiting, leg cramps, hypesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. Most Commonly Reported AEs (Incidence >= 2%) in Patients on Cilostazol 50 mg twice daily. or 100 mg twice daily. and Occurring at a Rate in the 100 mg twice daily. Group Higher Than in Patients on Placebo Adverse Events (AEs) by Body System Cilostazol 50 mg twice daily. (N=303)% Cilostazol 100 mg twice daily. (N=998)% Placebo (N=973)% BODY AS A WHOLE Abdominal pain 4 5 3 Back pain 6 7 6 Headache 27 34 14 Infection 14 10 8 CARDIOVASCULAR Palpitation 5 10 1 Tachycardia 4 4 1 DIGESTIVE Abnormal stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 METABOLIC & NUTRITIONAL Peripheral edema 9 7 4 MUSCULO-SKELETAL Myalgia 2 3 2 NERVOUS Dizziness 9 10 6 Vertigo 3 1 1 RESPIRATORY Cough increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (< 2%) that were experienced by patients exposed to cilostazol 50 mg twice daily. or 100 mg twice daily. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg twice daily. group greater than in the placebo group, regardless of suspected drug relationship, are listed below. Body as a whole Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal hemorrhage. Cardiovascular Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, hemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Digestive Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal hemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum hemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal hemorrhage, stomach ulcer, tongue edema. Endocrine Diabetes mellitus. Hemic and Lymphatic Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Metabolic and Nutritional Increased creatinine, gout, hyperlipemia, hyperuricemia. Musculoskeletal Arthralgia, bone pain, bursitis. Nervous Anxiety, insomnia, neuralgia. Respiratory Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Skin and Appendages Dry skin, furunculosis, skin hypertrophy, urticaria. Special Senses Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye hemorrhage, retinal hemorrhage, tinnitus. Urogenital Albuminuria, cystitis, urinary frequency, vaginal hemorrhage, vaginitis. Post-Marketing Experience The following adverse drug reactions (ADRs) to cilostazol have been reported worldwide since the launch of cilostazol in the US. 1. Blood and lymphatic system disorders -Agranulocytosis, aplastic anemia, granulocytopenia, pancytopenia, thrombocytopenia, leukopenia, bleeding tendency 2. Cardiac disorders -Torsades de pointes, QTc prolongation (torsades de pointes and QTc prolongation occurred in patients with cardiac disorders, e.g. complete atrioventricular block, cardiac failure and bradyarrythmia, when treated with cilostazol. Cilostazol was used \"off label\" due to its positive chronotropic action) 3. Gastrointestinal disorders -Gastrointestinal hemorrhage 4. General disorders and administration site conditions -Pain, chest pain, hot flushes 5. Hepatobiliary disorders -Hepatic dysfunction/abnormal liver function tests, jaundice 6. Injury, poisoning and procedural complications -Extradural hematoma and subdural hematoma 7. Investigations -Blood glucose increased, blood uric acid increased, platelet count decreased, white blood cell count decreased, increase in BUN (blood urea increased), blood pressure increase 8. Nervous system disorders -Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident 9. Respiratory, thoracic and mediastinal disorders -Pulmonary hemorrhage, interstitial pneumonia 10. Skin and subcutaneous tissue disorders -Hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa) 11. Vascular disorders -Subacute thrombosis (these cases of subacute thrombosis occurred in patients treated with aspirin and \"off label\" use of cilostazol for prevention of thrombotic complication after coronary stenting)"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=21
Page 21 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "drug_interactions": [
        "Drug Interactions Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP34 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients currently treated with diltiazem, an inhibitor of CYP3A4 (see : ). Cilostazol does not, however, appear to cause increased blood levels of drug metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to CYP3A4 inhibition. CLINICAL PHARMACOLOGY Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions"
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2274 patients exposed to either 50 or 100 mg b.i.d. cilostazol (N=1301)or placebo (N=973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >=3% of patients treated with cilostazol 50 or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with cilostazol 50 mg b.i.d., 100 mg b.i.d, or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >=2% of patients treated with cilostazol 50 or 100 mg b.i.d., are shown in the table (below). Other events seen with an incidence of >=2%, but occurring in the placebo group at least as frequently as in the 100 mg b.i.d. group, were: asthenia, hypertension, vomiting, leg cramps, hyperesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. Most Commonly Reported AEs (Incidence >=2%) in Patients on Cilostazol 50 mg b.i.d. or 100 mg b.i.d. and Occurring at a Rate in the 100 mg b.i.d. Group Higher Than in Patients on Placebo Adverse Events (AEs) By Body System Cilostazol 50 mg b.i.d. (N=303) % Cilostazol 100 mg b.i.d. (N=998) % Placebo (N=973) % Body as a Whole Abdominal Pain 4 5 3 Back Pain 6 7 6 Headache 27 34 14 Infection 14 10 8 Cardiovascular Palpitation 5 10 1 Tachycardia 4 4 1 Digestive Abnormal Stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 Metabolic & Nutritional Peripheral Edema 9 7 4 Musculoskeletal Myalgia 2 3 2 Nervous Dizziness 9 10 6 Vertigo 3 1 1 Respiratory Cough Increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (<2%) that were experienced by patients exposed to cilostazol 50 mg b.i.d. or 100 mg b.i.d. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg b.i.d. group greater than in the placebo group, regardless of suspected drug relationship, are listed below. : Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal hemorrhage. Body as a whole : Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, hemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Cardiovascular : Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal hemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum hemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal hemorrhage, stomach ulcer, tongue edema. Digestive : Diabetes mellitus. Endocrine : Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Hemic and Lymphatic : Increased creatinine, gout, hyperlipemia, hyperuricemia. Metabolic and Nutritional : Arthralgia, bone pain, bursitis. Musculoskeletal : Anxiety, insomnia, neuralgia. Nervous : Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Respiratory : Dry skin, furunculosis, skin hypertrophy, urticaria. Skin and Appendages : Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye hemorrhage, retinal hemorrhage, tinnitus. Special Senses : Albuminuria, cystitis, urinary frequency, vaginal hemorrhage, vaginitis. Urogenital Post-Marketing Experience The following events have been reported spontaneously from worldwide post-marketing experience since the launch of cilostazol in the US. Agranulocytosis, aplastic anemia, granulocytopenia, thrombocytopenia, leukopenia, bleeding tendency Blood and Lymphatic System Disorders: Torsades de pointes, QTc prolongation Cardiac Disorders: (torsades de pointes and QTc prolongation occurred in patients with cardiac disorders, e.g. complete atrioventricular block, cardiac failure and bradyarrythmia, when treated with cilostazol. Cilostazol was used \"off label\" due to its positive chronotropic action) Gastrointestinal hemorrhage Gastrointestinal Disorders: Pain, chest pain, hot flushes General Disorders and Administration Site Conditions: Hepatic dysfunction/abnormal liver function tests, jaundice Hepatobiliary Disorders: Extradural hematoma and subdural hematoma Injury, Poisoning and Procedural Complications: Blood glucose increased, blood uric acid increased, platelet count decreased, white blood cell count decreased, increase in BUN (blood urea increased), blood pressure increase Investigations: Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident Nervous System Disorders: Pulmonary hemorrhage, interstitial pneumonia Respiratory, Thoracic and Mediastinal Disorders: Hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa) Skin and Subcutaneous Tissue Disorders: Subacute thrombosis (these cases of subacute thrombosis occurred in patients treated with aspirin and \"off label\" use of cilostazol for prevention of thrombotic complication after coronary stenting) Vascular Disorders:"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=22
Page 22 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "drug_interactions": [
        "Drug Interactions Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to CYP3A4 inhibition."
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2274 patients exposed to either 50 or 100 mg b.i.d. cilostazol (n=1301) or placebo (n=973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >= 3% of patients treated with cilostazol 50 or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with cilostazol 50 mg b.i.d., 100 mg b.i.d, or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >= 2% of patients treated with cilostazol 50 or 100 mg b.i.d., are shown in the table (below). Other events seen with an incidence of >= 2%, but occurring in the placebo group at least as frequently as in the 100 mg b.i.d. group were: asthenia, hypertension, vomiting, leg cramps, hyperesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. Most Commonly Reported AEs (Incidence >=2%) in Patients on Cilostazol 50 mg b.i.d. or 100 mg b.i.d. and Occurring at a Rate in the 100 mg b.i.d. Group Higher Than in Patients on Placebo Adverse Events (AEs) by Body System Cilostazol 50 mg b.i.d. (N=303) % Cilostazol 100 mg b.i.d. (N=998) % Placebo (N=973) % BODY AS A WHOLE Abdominal pain 4 5 3 Back pain 6 7 6 Headache 27 34 14 Infection 14 10 8 CARDIOVASCULAR Palpitation 5 10 1 Tachycardia 4 4 1 DIGESTIVE Abnormal stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 METABOLIC & NUTRITIONAL Peripheral edema 9 7 4 MUSCULO-SKELETAL Myalgia 2 3 2 NERVOUS Dizziness 9 10 6 Vertigo 3 1 1 RESPIRATORY Cough increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (<2%) that were experienced by patients exposed to cilostazol 50 mg b.i.d. or 100 mg b.i.d. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg b.i.d. group greater than in the placebo group, regardless of suspected drug relationship, are listed below. Body As a Whole Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal hemorrhage. Cardiovascular Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, hemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Digestive Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal hemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum hemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal hemorrhage, stomach ulcer, tongue edema. Endocrine Diabetes mellitus. Hemic and Lymphatic Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Metabolic and Nutritional Increased creatinine, gout, hyperlipemia, hyperuricemia. Musculoskeletal Arthralgia, bone pain, bursitis. Nervous Anxiety, insomnia, neuralgia. Respiratory Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Skin and Appendages Dry skin, furunculosis, skin hypertrophy, urticaria. Special Senses Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye hemorrhage, retinal hemorrhage, tinnitus. Urogenital Albuminuria, cystitis, urinary frequency, vaginal hemorrhage, vaginitis. Post-Marketing Experience The following events have been reported spontaneously from worldwide post-marketing experience since the launch of cilostazol in the US. Blood and lymphatic system disorders - agranulocytosis, aplastic anemia, granulocytopenia, thrombocytopenia, leukopenia, bleeding tendency Cardiac disorders - Torsades de pointes, QTc prolongation ( Torsades de pointes and QTc prolongation occurred in patients with cardiac disorders, e.g. complete atrioventricular block, cardiac failure and bradyarrythmia, when treated with cilostazol. Cilostazol was used "off label" due to its positive chronotropic action.) Gastrointestinal disorders - gastrointestinal haemorrhage General disorders and administration site conditions - pain, chest pain, hot flushes Hepatobiliary disorders - hepatic dysfunction/abnormal liver function tests, jaundice Injury, poisoning and procedural complications - extradural haematoma and subdural haematoma Investigations - blood glucose increased, blood uric acid increased, platelet count decreased, white blood cell count decreased, increase in BUN (blood urea increased), blood pressure increase Nervous system disorders - intracranial haemorrhage, cerebral haemorrhage, cerebrovascular accident Respiratory, thoracic and mediastinal disorders - pulmonary haemorrhage, interstitial pneumonia Skin and subcutaneous tissue disorders - haemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa) Vascular disorders - subacute thrombosis (These cases of subacute thrombosis occurred in patients treated with aspirin and "off label" use of cilostazol for prevention of thrombotic complication after coronary stenting.)"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Cilostazol&limit=1&skip=23
Page 23 of 24
        "generic_name": [
          "CILOSTAZOL"
        "brand_name": [
          "Cilostazol"
 
      "drug_interactions": [
        "Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions Cilostazol could have pharmacodynamic interactions with other inhibitors of platelet function and pharmacokinetic interactions because of effects of other drugs on its metabolism by CYP3A4 or CYP2C19. A reduced dose of cilostazol should be considered when taken concomitantly with CYP3A4 or CYP2C19 inhibitors. Cilostazol does not appear to inhibit CYP3A4 (see Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions, Lovastatin ). Aspirin Short-term (<= 4 days) coadministration of aspirin with cilostazol increased the inhibition of ADP-induced ex vivo platelet aggregation by 22% to 37% when compared to either aspirin or cilostazol alone. Short-term (<= 4 days) coadministration of aspirin with cilostazol increased the inhibition of arachidonic acid-induced ex vivo platelet aggregation by 20% compared to cilostazol alone and by 48% compared to aspirin alone. However, short-term coadministration of aspirin with cilostazol had no clinically significant impact on PT, aPTT, or bleeding time compared to aspirin alone. Effects of long-term coadministration in the general population are unknown. In eight randomized, placebo-controlled, double-blind clinical trials, aspirin was coadministered with cilostazol to 201 patients. The most frequent doses and mean durations of aspirin therapy were 75 to 81 mg daily for 137 days (107 patients) and 325 mg daily for 54 days (85 patients). There was no apparent increase in incidence of hemorrhagic adverse effects in patients taking cilostazol and aspirin compared to patients taking placebo and equivalent doses of aspirin. Warfarin The cytochrome P-450 isoenzymes involved in the metabolism of R-warfarin are CYP3A4, CYP1A2, and CYP2C19, and in the metabolism of S-warfarin, CYP2C9. Cilostazol did not inhibit either the metabolism or the pharmacologic effects (PT, aPTT, bleeding time, or platelet aggregation) of R- and S-warfarin after a single 25 mg dose of warfarin. The effect of concomitant multiple dosing of warfarin and cilostazol on the pharmacokinetics and pharmacodynamics of both drugs is unknown. Clopidogrel Multiple doses of clopidogrel do not significantly increase steady state plasma concentrations of cilostazol. Inhibitors of CYP3A4 Strong Inhibitors of CYP3A4 A priming dose of ketoconazole 400 mg (a strong inhibitor of CYP3A4), was given one day prior to coadministration of single doses of ketoconazole 400 mg and cilostazol 100 mg. This regimen increased cilostazol Cmax by 94% and AUC by 117%. Other strong inhibitors of CYP3A4, such as itraconazole, fluconazole, miconazole, fluvoxamine, fluoxetine, nefazodone, and sertraline, would be expected to have a similar effect (see DOSAGE AND ADMINISTRATION). Moderate Inhibitors of CYP3A4 Erythromycin and other macrolide antibiotics: Erythromycin is a moderately strong inhibitor of CYP3A4. Coadministration of erythromycin 500 mg q 8h with a single dose of cilostazol 100 mg increased cilostazol Cmax by 47% and AUC by 73%. Inhibition of cilostazol metabolism by erythromycin increased the AUC of 4'-trans-hydroxy-cilostazol by 141%. Other macrolide antibiotics (e.g., clarithromycin), but not all (e.g., azithromycin), would be expected to have a similar effect (see DOSAGE AND ADMINISTRATION). Diltiazem: Diltiazem 180 mg decreased the clearance of cilostazol by ~ 30%. Cilostazol Cmax increased ~ 30% and AUC increased ~ 40% (see DOSAGE AND ADMINISTRATION). Grapefruit Juice: Grapefruit juice increased the Cmax of cilostazol by ~ 50%, but had no effect on AUC. Inhibitors of CYP2C19 Omeprazole Coadministration of omeprazole did not significantly affect the metabolism of cilostazol, but the systemic exposure to 3,4-dehydro-cilostazol was increased by 69%, probably the result of omeprazole's potent inhibition of CYP2C19 (see DOSAGE AND ADMINISTRATION). Quinidine Concomitant administration of quinidine with a single dose of cilostazol 100 mg did not alter cilostazol pharmacokinetics. Lovastatin The concomitant administration of lovastatin with cilostazol decreases cilostazol Css, max and AUC by 15%. There is also a decrease, although nonsignificant, in cilostazol metabolite concentrations. Coadministration of cilostazol with lovastatin increases lovastatin and -hydroxi lovastatin AUC approximately 70%. This is most likely clinically insignificant.",
      "adverse_reactions": [
        "ADVERSE REACTIONS Adverse events were assessed in eight placebo-controlled clinical trials involving 2274 patients exposed to either 50 or 100 mg b.i.d. cilostazol (n = 1301) or placebo (n = 973), with a median treatment duration of 127 days for patients on cilostazol and 134 days for patients on placebo. The only adverse event resulting in discontinuation of therapy in >= 3% of patients treated with cilostazol 50 or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with cilostazol 50 mg b.i.d., 100 mg b.i.d, or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo. The most commonly reported adverse events, occurring in >= 2% of patients treated with cilostazol 50 or 100 mg b.i.d., are shown in the table (below). Other events seen with an incidence of >= 2%, but occurring in the placebo group at least as frequently as in the 100 mg b.i.d. group were: asthenia, hypertension, vomiting, leg cramps, hypesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. Most Commonly Reported AEs (Incidence >= 2%) in Patients on Cilostazol 50 mg b.i.d. or 100 mg b.i.d. and Occurring at a Rate in the 100 mg b.i.d. Group Higher Than in Patients on Placebo Adverse Events (AEs) by Body System Cilostazol 50 mg b.i.d. (N = 303) % Cilostazol 100 mg b.i.d. (N = 998) % Placebo (N = 973) % BODY AS A WHOLE Abdominal pain 4 5 3 Back pain 6 7 6 Headache 27 34 14 Infection 14 10 8 CARDIOVASCULAR Palpitation 5 10 1 Tachycardia 4 4 1 DIGESTIVE Abnormal stools 12 15 4 Diarrhea 12 19 7 Dyspepsia 6 6 4 Flatulence 2 3 2 Nausea 6 7 6 METABOLIC & NUTRITIONAL Peripheral edema 9 7 4 MUSCULO-SKELETAL Myalgia 2 3 2 NERVOUS Dizziness 9 10 6 Vertigo 3 1 1 RESPIRATORY Cough increased 3 4 3 Pharyngitis 7 10 7 Rhinitis 12 7 5 Less frequent adverse events (< 2%) that were experienced by patients exposed to cilostazol 50 mg b.i.d. or 100 mg b.i.d. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg b.i.d. group greater than in the placebo group, regardless of suspected drug relationship, are listed below. Body as a whole: Chills, face edema, fever, generalized edema, malaise, neck rigidity, pelvic pain, retroperitoneal hemorrhage. Cardiovascular: Atrial fibrillation, atrial flutter, cerebral infarct, cerebral ischemia, congestive heart failure, heart arrest, hemorrhage, hypotension, myocardial infarction, myocardial ischemia, nodal arrhythmia, postural hypotension, supraventricular tachycardia, syncope, varicose vein, vasodilation, ventricular extrasystoles, ventricular tachycardia. Digestive: Anorexia, cholelithiasis, colitis, duodenal ulcer, duodenitis, esophageal hemorrhage, esophagitis, increased GGT, gastritis, gastroenteritis, gum hemorrhage, hematemesis, melena, peptic ulcer, periodontal abscess, rectal hemorrhage, stomach ulcer, tongue edema. Endocrine: Diabetes mellitus. Hemic and Lymphatic: Anemia, ecchymosis, iron deficiency anemia, polycythemia, purpura. Metabolic and Nutritional: Increased creatinine, gout, hyperlipemia, hyperuricemia. Musculoskeletal: Arthralgia, bone pain, bursitis. Nervous: Anxiety, insomnia, neuralgia. Respiratory: Asthma, epistaxis, hemoptysis, pneumonia, sinusitis. Skin and Appendages: Dry skin, furunculosis, skin hypertrophy, urticaria. Special Senses: Amblyopia, blindness, conjunctivitis, diplopia, ear pain, eye hemorrhage, retinal hemorrhage, tinnitus. Urogenital: Albuminuria, cystitis, urinary frequency, vaginal hemorrhage, vaginitis. Postmarketing Experience The following events have been reported spontaneously from worldwide postmarketing experience since the launch of cilostazol in the U.S. Blood and lymphatic system disorders: Agranulocytosis, aplastic anemia, granulocytopenia, thrombocytopenia, leukopenia, bleeding tendency Cardiac disorders: Torsade de pointes, QTc prolongation (t orsade de pointes and QTc prolongation occurred in patients with cardiac disorders, e.g., complete atrioventricular block, cardiac failure and bradyarrythmia, when treated with cilostazol. Cilostazol was used "off label" due to its positive chronotropic action) Gastrointestinal disorders: Gastrointestinal hemorrhage General disorders and administration site conditions: Pain, chest pain, hot flushes Hepatobiliary disorders: Hepatic dysfunction/abnormal liver function tests, jaundice Injury, poisoning and procedural complications: Extradural hematoma and subdural hematoma Investigations: Blood glucose increased, blood uric acid increased, platelet count decreased, white blood cell count decreased, increase in BUN (blood urea increased), blood pressure increase Nervous system disorders: Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident Respiratory, thoracic and mediastinal disorders: Pulmonary hemorrhage, interstitial pneumonia Skin and subcutaneous tissue disorders: Hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa) Vascular disorders: Subacute thrombosis (these cases of subacute thrombosis occurred in patients treated with aspirin and "off label" use of cilostazol for prevention of thrombotic complication after coronary stenting)"
 
 
--------------------------------------------------------------------------------------------------------------------
